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Abstract 
Investigating phagocytic markers in Juvenile -onset Systemic Lupus 
Erythematosus (JSLE) monocytes and macrophages  
David Andrew Harris 
 
Background Juvenile-onset systemic lupus erythematosus (JSLE) is a chronic, severe, multi-systemic 
autoimmune disease. Impaired phagocytic function has been implicated as an initial step in the 
pathogenesis of this disease, in relation to the clearance of cells undergoing apoptosis. The 
apoptotic process has been shown to be dysregulated in neutrophils, and these cells, and others, are 
thought to represent a burden of autoantigen-presenting apoptotic cells. After a sequence of 
immune cell activation, the result is the production of autoantibodies forming immune complexes 
which cause deleterious effects at end-organs. As key phagocytes, the phenotypes of JSLE 
macrophages, and their precursors monocytes, have been investigated to determine the extent of 
their role in the development of JSLE. 
Aim To elucidate phenotype and phagocytic function of monocytes and macrophages as a potential 
important contributing factor to the development of JSLE. 
Methods Monocytes were separated from processed whole blood of JSLE patients and paediatric 
healthy controls (HC), and either retained or cultured to macrophages, with the RNA extracted. RNA 
was converted to cDNA and real-time qPCR performed with primers for CD36, MER, and CR3, with 
expression standardised against that of β2M. Concentrations of soluble MER (sMER) were measured 
in JSLE, JIA and HC plasma samples by ELISA. These samples were diluted to a concentration of 1 in 
5, following validation and optimisation conducted through spike and recovery. Adult HC monocytes 
were incubated with pHrodo E. coli for 30 minutes in JSLE and control plasma and serum, and 
phagocytosis was measured by flow cytometry. Adult HC monocytes were exposed to a number of 
environments (LPS, IFNα, TNFα, apoptotic neutrophils) for 2 and 6 hours. Supernatant was extracted 
and tested by human total MER ELISA, and monocyte RNA was extracted and RT-qPCR performed. 
Results Increased mRNA levels of CD36 were present in JSLE monocytes (p=0.025) but no differences 
found with MER or CR3 expression compared with HC monocytes, no differences in expression of 
these markers in macrophages. CR3 was down-regulated in both JSLE monocytes and macrophages, 
but no other differences were statistically significant.  The concentrations of sMER were significantly 
greater in JSLE patients compared with HC (p<0.001) and JIA patients (p=0.014). Phagocytosis of E. 
coli was decreased when adult HC monocytes were incubated in JSLE serum and plasma compared 
with controls, though differences were not statistically significant. No MER cleavage was detected 
following exposure of monocytes to test conditions. qPCR results for CD36, MER and CR3 expression 
in response to monocyte stimulation were equivocal. 
Discussion Differences were detected in receptor expression of CD36 between JSLE and control 
monocytes, an important receptor in apoptotic cell clearance. sMER is present at a much greater 
concentration in JSLE patients than inflammatory controls and HC, and this can be expected to 
negatively impact upon apoptotic cell clearance due to reduced cell expression and by competing for 
ligand. Phagocytosis of bacteria by monocytes appeared to be impaired when exposed to JSLE 
environments, and this may suggest the involvement of extracellular factors in the proposed failure 
of effective apoptotic cell clearance. 
Conclusion This study has identified a number of important distinguishing features concerning the 
phagocytic markers of JSLE monocytes and macrophages and those of HC. It has also identified a 
number of extracellular features, including increased presence of sMER, which may significantly 
influence their function, potentially reducing the capacity for apoptotic cell clearance to occur, 
resulting in autoantigen presentation. 
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1 Introduction 
 
The subject of this thesis is the autoimmune disease juvenile-onset systemic lupus 
erythematosus (JSLE). The content is, in particular, focused upon monocytes and 
macrophages in this disease and their potential role in its associated development and 
process. A failure of apoptotic cell clearance is believed to be a key early step in the 
pathogenesis of adult-onset SLE, and as key phagocytes these cells have been investigated 
as to their potential involvement in this. 
 
1.1 Cells of the innate immune system 
 
Phagocytosis is crucial to the appropriate removal of foreign agents and dying cells. Two of 
the cells of the immune system most responsible for this process are monocytes and 
macrophages. 
 
1.1.1 Monocytes 
 
Monocytes are generated from myelocytic lineage, deriving from the myeloblast (see 
Figure 1-1), also the common haemopoetic stem cell of neutrophils, eosinophils and 
basophils (1). Formed in the bone marrow (2), monocytes are stored both there and in the 
spleen (3) until required. They typically circulate for between one and three days (4), 
roaming in case their phagocytic functions may be required, after which point they tend to 
differentiate into macrophages in the tissues (1). Monocytes are also the precursors of the 
dendritic cell (5) (see Figure 1-1), another phagocyte, but whose main function is 
considered to be the presentation of antigens to T-lymphocytes, and as such acts as a link 
between the innate and adaptive immune system (6). The development of monocytes and 
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their subsequent differentiation into macrophages or dendritic cells is illustrated in Figure 
1-1.  The monocyte’s involvement in immunity is considered to be most importantly 
microbial phagocytosis (7), but also includes phagocytosis of dying cells, antigen 
presentation and immunomodulation (through the secretion of cytokines) (2). 
 
 
Figure 1-1 Monocyte, Macrophage and Dendritic Cell developmental lineage (8) 
 
CDP, common DC progenitor; CMP, common myeloid progenitor; GMP, granulocyte and macrophage 
progenitor; HSC, haematopoietic stem cell; MDP, macrophage and DC progenitor. 
 
 
Monocytes are broadly divisible by their cluster of differentiation (CD) marker expression 
into CD14+CD16- and CD14+CD16+ populations (8). The former is referred to as “classical” 
and comprises around 90% of monocytes, while the latter is a minority of “non-classical” 
monocytes first identified over 20 years ago (9), and this group can be further divided 
according to CD14 expression, i.e. CD14dimCD16+ and CD14highCD16+. CD14 is a 
lipopolysaccharide (LPS) receptor complex (10), with LPS typically found on bacteria, and 
CD16 is the FcγR III immunoglobulin receptor (11). CD14dimCD16+-monocytes are 
considered to be pro-inflammatory monocytes, due to observed increased numbers in 
infection(12), with toll-like receptor (TLR) stimulation manifesting increased tumour 
necrosis factor (TNF-α) (13) and decreased interleukin (IL)-10 secretion (13). The other 
CD16+ subset, CD14highCD16+, is considered anti-inflammatory due to its propensity to 
secrete large quantities of IL-10 (14). 
 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte 
system in the molecular age. Nature reviews Immunology. 
2011;11(11):788-98. 
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1.1.2 Macrophages 
 
The end-stage development of monocytes, macrophages are often described as 
professional phagocytes as they are able to engulf larger particles and persist to 
phagocytose numerous organisms, cells, particles and agents and continue to function for 
weeks or months. Differentiation of monocytes in the tissues results in distinct types of 
macrophages: a group that are able to mobilise where needed, but also a fixed group that 
remain localised for months or years, performing the required functions in-situ. Examples 
of the latter include the Kupffer cells in the liver, mesangial cells in the kidneys, and 
alveolar macrophages in the lungs (15), see Figure 1-2. The dynamic system of circulating 
monocytes and free and fixed macrophages is known as the reticuloendothelial, or, more 
contemporarily, the mononuclear phagocyte system (1).  
 
 
Figure 1-2 Homeostatic functions of tissue macrophages (15) 
 
Populations of macrophages are located around the body with context-appropriate roles including 
phagocytosis, antigen presentation and immune suppression. 
 
 
Macrophages clear around 2 x 1011 red blood cells every day, and in doing so accept a huge 
burden without which the human body could not hope to survive (1). They also clear 
cellular debris generated in tissue remodelling and are responsible for the removal of cells 
undergoing apoptosis (1) (programmed cell death, see section 1.2). In the case of apoptotic 
cell removal, associated-receptors either fail to induce pro-inflammatory signals, or act to 
induce anti-inflammatory signals (1). This is in stark contrast to the macrophage response 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
Murray PJ, Wynn TA. Protective and pathogenic functions of 
macrophage subsets. Nature reviews Immunology. 2011;11(11):723-37. 
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to pathogens or necrosis, which is pro-inflammatory by necessity, thereby activating the 
wider immune system. 
 
Macrophages have been historically categorised into 2 groups, M1 and M2 (1). M1 
macrophages have been described as “classically activated” and are responsible for 
defence against pathogens and in anti-tumour immunity (15). M2 macrophages indicate 
“alternative activation” and are mostly concerned with anti-inflammatory and regulating 
wound healing (15). Over time, the M2 group has been attributed to increasingly-diverse 
roles (including induction by apoptotic cells), and this traditional perspective is no longer 
universally supported (16) as macrophages are now believed to occupy a fairly broad 
phenotypic spectrum (1). However, what these macrophages do have in common is the 
ability to either induce host defence, anti-tumour immunity and pro-inflammatory 
responses or the ability to suppress those functions (17). 
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1.2 Apoptosis 
Apoptosis, as first described by Kerr et al (18) in 1972, is a process of controlled cell death 
designed to minimise damage to the surrounding cells. The alternative method of cell 
death is necrosis, occurring when a cell can no longer maintain membrane integrity (19), 
leading to the release of intracellular proteins and enzymes and the induction of a strong 
inflammatory response. There are three main ways that the apoptosis process may be 
initiated: by the extrinsic, intrinsic or granzyme B pathways (20) (see Figure 1-3). 
Ultimately, these pathways result in the activation of the foremost effectors, the caspases: 
caspase-3, caspase-6, and caspase-7 (20), which are responsible for proteolysis. If not 
appropriately dealt with, apoptosing cells are allowed to subsequently undergo secondary 
necrosis (19), through which they may activate the Fcγ receptors or TLRs on macrophages 
leading to a pro-inflammatory response, or eventually rupture, exposing the immediate 
environment to their toxic elements. 
 
 
 
 
Figure 1-3 Caspase activation pathways (extrinsic, intrinsic and granzyme B) for the induction of apoptosis 
(20) 
All three pathways result in the activation of caspases, which are responsible for the proteolysis associated with 
cell death. APAF1, apoptotic protease-activating factor-1; BAD, BCL-2 antagonist of cell death; BAK, BCL-2-
antagonist/killer-1; BAX, BCL-2-associated X protein; BCL-2, B-cell lymphoma-2; BID, BH3-interacting domain 
death agonist; BIK, BCL-2-interacting killer, BIM, BCL-2-like-11; BMF, BCL-2 modifying factor; FADD, Fas-
associated death domain protein; FasL, Fas ligand; HRK, harakiri (or death protein-5); PUMA, BCL-2 binding 
component-3; tBID, truncated BID; TNFα, tumour necrosis factor alpha. 
 
 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the 
cellular level. Nature reviews Molecular cell biology. 2008;9(3):231-41. 
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The extrinsic pathway is activated by a process in which ligands, such as TNF-α or Fas ligand 
(FasL), bind to a cell’s death receptors, stimulating adaptor proteins such as the Fas-
associated death domain protein (21). This recruits and activates caspase-8, commencing a 
caspase cascade (see Figure 1-3). 
 
In the intrinsic pathway, intracellular stimuli (e.g. DNA damage) activate BH3-only proteins. 
There must be sufficient activation in order to overcome the inhibitory effects of the B-cell 
lymphoma-2 family, to then go on to promote BAK-BAX oligomer production (within the 
mitochondria) (20). This causes cytochrome c release into the cytosol, triggering the 
formation of an apoptosome, a large quaternary protein which recruits pro-caspase 9 (22), 
converting it into its activated form, caspase 9 (see Figure 1-3).  
 
Through the granzyme B pathway, cytotoxic T lymphocytes or natural killer cells release 
granules of granzymes and perforin (23). Perforin oligomerises in the cell membrane, 
forming a channel to facilitate the passage of the granzymes into the cell. Granzyme B can 
then activate caspases 3 and 7, and BH3-interacting domain death agonist (23) (so can also 
act upon part of the intrinsic pathway as well as through caspases). 
 
During apoptosis, inside the cell the nucleus condenses and the DNA hydrolyses and 
fragments (20). Fragmentation of the Golgi complex, endoplasmic reticulum and 
mitochondria also occurs, and proteins are released from the inter-membrane space of the 
mitochondria, one of which, cytochrome c, forms part of an aforementioned mechanism of 
apoptosis (20). 
 
Externally, an apoptosing cell retracts from those surrounding it and becomes rounded, 
and plasma membrane blebbing occurs, in which the cytoskeleton separates from the 
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plasma membrane. Blebs are vesicles, of which some burst whilst others break-off as 
apoptotic bodies (24). Importantly, from a homeostatic point of view, the changes that 
occur visibly separate these apoptotic cells from their non-apoptotic counterparts, alerting 
the phagocytes to the impending need to clear them (25). Apoptotic body formation is 
thought to confer an advantage to the efficiency of phagocytosis, with the suggestion that 
these bodies are produced in order to facilitate the clearance of the apoptotic cell (20). 
 
Communication is important in cell death; dying cells secrete a “find me” signal, which 
enables macrophages to seek out these apoptosing cells by chemotaxis (26). Much is still 
unknown about these secretions, but proposed molecules include lysophosphatidylcholine, 
S19 (a ribosomal protein), and animoacyl-tRNA synthetases (20). 
 
Macrophages and other phagocytes need to be able to differentiate an apoptosing cell 
from a non-apoptosing cell, and in order that the process may occur before progression to 
secondary necrosis, recognition needs to take place early in apoptosis. This is achieved by 
the “eat me” receptors expressed on the surface of the dying cell, enabling recognition of 
these cells.  The most distinctive external elements of an apoptosing cell is the loss of 
phospholipid asymmetry and exposure of phosphatidylserine (PS), and it is this 
transformation that is imperative for phagocytosis to occur (27). It is asserted that, as PS is 
often found to collect externally, these may comprise large recognition domains on 
membrane blebs (27, 28). 
 
The external changes of the apoptotic cell are imperative so that non-apoptosing cells are 
spared from phagocytosis; that there is instead a response targeted exclusively at apoptotic 
cells. Although much remains unknown about the exact nature of many of the precise 
changes that occur, and their potential interactions with the phagocyte, there are a 
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number of identified ligands with evidence for their role in this process. PS, normally a 
constituent of the inner-part of the phospholipid cell membrane, redistributes to the 
outside in the apoptosing cell (29). The asymmetrical cell membrane is so-called due to the 
usual presence of the vast majority of phospholipids with attachments including PS and 
phosphatidylethanolamine, located on the cytoplasmic side of the cell membrane (29). This 
PS status quo is maintained by an ATP-dependent aminophospholipid translocase that 
transports PS from the outside to the inside in normal, non-apoptotic cells (29). Through 
various apoptosis-associated mechanisms, those which previously maintained it as internal 
become inactive, allowing PS to become concentrated on the outside (30). A study has 
indicated that PS externalisation is the result of its oxidation secondary to cytochrome c 
(31), and that this oxidation may contribute to the attraction of opsonins. External changes 
such as those outlined are often described as “eat me” signals, encouraging the 
phagocytosis of the apoptotic cell. 
 
With regards to PS, research has shown that a phagocyte requires at least one receptor to 
tether and another to internalise the apoptotic cell (32). The integrins (e.g. αvβ3 and αvβ5) 
and integrin-associated proteins (e.g. CD36) are generally associated with the tethering 
process, and the tyrosine kinase receptor MER is one receptor considered important in 
apoptotic cell internalisation. Of these, αvβ5 and MER are suggested to act in concert, and 
together enable efficient apoptotic cell uptake to occur. These and other receptors are 
discussed in further detail in section 0.  
 
1.2.1 Apoptosis and disease 
In humans, every second, around 100,000 cells are produced by mitosis, and around the 
same amount die by apoptosis (33). It is imperative that this is well-regulated to maintain 
the equilibrium (34). Broadly speaking, aberrant apoptosis can be subdivided into two 
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opposing groups; either reduced or excessive apoptosis. It has been estimated that 
dysregulated apoptosis is contributory towards around half of diseases currently 
inadequately treated (35). Apoptotic failure is an important step in the development of 
cancer, whilst the occurrence of excessive apoptosis has been observed in the disease 
processes of neurodegenerative conditions, heart failure, and AIDS (acquired immune 
deficiency syndrome) (34). Autoimmune diseases, meanwhile, have been implicated with 
both excessive and reduced apoptosis (34). Apoptosis is a vitally important process which 
must be well-regulated, and if not can result in the manifestation of disease. Increased rate 
of apoptosis is postulated to be an important early step in the pathogenesis of systemic 
lupus erythematosus (SLE) (36). In health, the apoptotic cells are cleared effectively by the 
body’s immune system, so it is important to consider this process in detail. 
 
1.2.2 Apoptosis and SLE 
In SLE, the rate of apoptosis of lymphocytes has been shown to be increased in vitro, 
compared to both healthy controls (HC) and rheumatoid arthritis controls (37). The rate of 
apoptosis was also found to correlate with disease activity. Ren et al investigated the rate 
of apoptosis in neutrophils, finding it to be significantly greater in SLE patients than 
controls. The introduction of SLE serum also induced a greater rate of apoptosis in these 
neutrophils (38). These results have been mirrored in JSLE neutrophils, with the cells 
themselves showing increased tendency to apoptose, but also with contribution from their 
(serum) environment (39). The apoptosis-inducing serum of JSLE has also been 
demonstrated in adult-onset SLE (40). Investigation of the blebs expressed during 
neutrophil apoptosis also found them to contain nuclear antigen, suggesting a potential 
source of autoantigen (41); against which an immune response would be mounted in the 
event of loss of self-tolerance. 
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1.3 Phagocytosis and the clearance of apoptotic cells 
Phagocytosis is the process of cellular ingestion, occurring through initial recognition and 
binding, resulting in internalisation and degradation (42). It is vitally important that the 
body may clear the senescent cells and infectious agents that would otherwise be free to 
accumulate or even proliferate (16). The capacity for a phagocyte to accomplish this is 
dependent on three main factors (43). First, a rougher surface increases a particle’s 
susceptibility to phagocytosis. Secondly, dead tissues and foreign particles lack protein 
coats which afford protection against phagocytes. Finally, the likelihood of phagocytosis 
can be increased by the involvement of other components of the immune system: 
antibodies, which adhere to the bacterial membrane, and complement, in particular C3, 
which is important in opsonisation (44).  
 
The process of phagocytosis varies depending on the specific particle in question. In 
general, internalisation is initiated by receptors on the phagocyte surface interacting with 
ligands on the particle. Polymerisation of actin occurs and the particle is internalised into a 
phagosome, which matures and the particle can be subsequently destroyed (1) through 
fusion with a cell lysosome, traditionally referred to as a “suicide bag” (45) for its role in 
protein and macromolecule turnover. 
 
It is clear that there are different mechanisms that macrophages can employ to internalise 
a dying cell. There is, however, no consensus as to whether there is one absolute method 
for each type of dying cell to be phagocytosed. The two main mechanisms described are 
illustrated in Figure 1-4. In the zipper mechanism, a sequential ligation of receptors form 
around the cell, engulfing it (46). In macropinocytosis, membrane ruffling occurs, encircling 
the cell and extracellular fluid into a pinosome (a fluid-filled vesicle) (47). Evidence suggests 
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that apoptotic cell uptake occurs through the zipper mechanism and it is necrotic (including 
secondary necrotic) cells that are internalised through macropinocytosis (48). 
 
 
 
Figure 1-4 The physical mechanisms of phagocytosis (46) 
The figure shows the two best-described methods of phagocytosis. In the zipper mechanism, sequential ligation 
of receptors leads to the engulfment of cells, whereas in stimulated macropinocytosis engulfment is achieved 
by membrane ruffling, allowing part of the phagocyte to encircle the cell and surrounding extracellular fluid. 
 
 
Considered more broadly, there are two distinct patterns to phagocytosis. When a 
microbial organism is engulfed, a pro-inflammatory process is engaged, activating the 
acquired immune response (49). This is important to instigate the recruitment of other 
elements of the immune system in a full scale response. In contrast, the hallmark of 
“normal” apoptotic cell phagocytosis is the absence of pro-inflammatory cytokine release, 
with instead the secretion of anti-inflammatory cytokines, actively preventing the 
activation of the innate and acquired immune systems (50). These anti-inflammatory 
secretions are often summarised by a process known as “tolerate me”, ensuring the 
apoptotic cell is dealt with in a self-limiting manner. The three stages of apoptotic cell 
clearance discussed in this section are graphically summarised in Figure 1-5. 
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Figure 1-5 The stages of apoptotic cell clearance (adapted from (51)) 
The figures show the three broad processes associated with the normal uptake of a dying cell. (a) ‘Find me’, in 
which the apoptotic cell releases chemotactic factors to induce the migration of phagocytes; (b) ‘eat me’, in 
which surface molecules including PS (PS) are expressed by the apoptotic cell to encourage phagocytosis; (c) 
‘tolerate me’, in which the phagocyte secretes anti-inflammatory agents to preclude immune system activation. 
IL-10, interleukin-10; TGF-β, tissue growth factor beta; PGE2, prostaglandin E2. 
 
 
1.3.1 Apoptotic cell clearance and disease 
Apoptotic cells that remain non-phagocytosed are left to undergo secondary necrosis. 
Subsequent phagocytosis of a secondarily-necrotic cell results in a pro-inflammatory 
response, or continued failure of phagocytosis inevitably results in cell rupture with the 
exposure of the cell’s toxic elements to the body. In the case of autoimmunity, cellular 
rupture will result in the release of intracellular antigens, against which the immune system 
may mount an inappropriate response. The relationship between ineffective apoptotic cell 
clearance and autoimmunity is now well-established (52). In respiratory disease, increased 
levels of apoptotic cells have been observed in the sputum and lung tissue of patients with 
diseases such as asthma and cystic fibrosis (53), but there is still uncertainty as to whether 
this is due to increased apoptosis or decreased clearance (50), though research has 
presented evidence of associated defective phagocytes (50). Further, aberrant clearance 
has been implicated in the development of pathologies included atherosclerosis and 
neurodegenerative disease, among others (50).  
 
1.3.2 Apoptotic cell clearance and SLE 
Impaired phagocytosis has had a long-standing historical association with SLE (54), 
reproduced more recently in the macrophage (55). Today, the hypothesised pathogenesis 
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of this complex, all-encompassing immune disorder positions this impairment as a first step 
in a series of subsequent downstream immunological dysfunctions. This, combined with a 
considered pro-apoptotic environment in SLE contributes to an accumulation of apoptotic 
cells.  
 
Impaired phagocyte function has an established and longstanding association with SLE, 
with published research dating back to 1969 (56). However, this impairment may be more a 
symptom of the disease than a causative element of the disease process. In more recent 
times, a number of papers have described the impairment of apoptotic cell phagocytosis in 
SLE. 
 
In research by Herrmann et al (55), phagocytosis of apoptotic cells by monocyte-derived 
macrophages was observed to be greater in control than in SLE cells. This seemed to 
suggest an intrinsic phagocyte defect of apoptotic cell clearance. Ren et al (38) also 
observed a decreased in the phagocytosis of apoptotic cells by SLE monocyte-derived 
macrophages. They also observed a marked increase of phagocytic performance in 
macrophages incubated in control serum, and a marked decrease in control macrophages 
incubated in SLE serum. The results suggested a combination of both the intrinsic, cellular 
factors and the extrinsic, serum factors. Tas et al (57) investigated phagocytosis by looking 
separately at binding and ingestion, finding that there was no difference between the 
ability of SLE and control monocyte-derived macrophages to bind apoptotic cells, but a 
decreased capability for SLE monocyte-derived macrophages to internalise apoptotic cells. 
This suggests a nuanced defect, or defects, underlying this difference. Evidence as to the 
role of cells versus the environment in SLE has been conflicting. 
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Bijl et al (58) investigated phagocytosis of apoptotic cells by monocyte-derived 
macrophages from SLE patients and HC, incubated in SLE or HC serum. There were no 
detected differences between the phagocytic performance of control and SLE monocyte-
derived macrophages in control serum. The difference arose when control monocyte-
derived macrophages were incubated with apoptotic cells in SLE serum, which was 
decreased compared with control serum, and active disease serum exerted a greater 
negative effect on phagocytosis than inactive disease serum. The research reported 
therefore suggests that it is SLE environmental factors, rather than intrinsic phagocyte 
failings which may impact upon apoptotic cell clearance. 
 
Other work has also investigated the potential role of complement in apoptotic cell 
clearance. Grevink et al (59) divided SLE patients according to their measured classical 
pathway haemolytic complement activity (deemed normal or low) and compared in vitro 
phagocytosis by control monocyte-derived macrophages of apoptotic cells in these control 
and SLE sera samples. There was no difference in detected phagocytosis between control 
and SLE, and nor did the level of complement activity appear to influence this. 
 
Baumann et al (60) identified, from SLE and control lymph node biopsy samples, a 
subgroup of SLE patients in whose germinal centres resided an excess of apoptotic cells and 
a relative deficiency of tingible body macrophages. They suggest that in this subgroup the 
accumulation of dying cells is caused by either this deficiency of macrophages or an 
impairment of clearance. The apoptotic cells disintegrate exposing autoantigens which 
ensure the survival of autoreactive B cells, as a potential source of SLE-associated 
autoantibodies. 
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1.4 Juvenile-onset Systemic Lupus Erythematosus 
 
Systemic lupus erythematosus (SLE) is a chronic, multi-systemic autoimmune disease. It is 
sometimes described as the prototypal autoimmune disease, as all the main elements of 
the immune system have been implicated in its pathogenesis (61). The course and severity 
of disease varies widely, with an often unpredictable pattern of relapse and remission. 
 
1.4.1 Epidemiology 
 
Juvenile-onset SLE (JSLE), meanwhile, is SLE diagnosed in a person before the age of 17 
(though there is a lack of consensus at which age JSLE should be distinguished from SLE). 
UK incidence has been estimated at 0.73 per 100,000 per year (62) (albeit JSLE was defined 
as SLE in those under 19 years – evidence of the grey area that is SLE age-segregation), and 
JSLE cases make up around 10-20% of all SLE cases. . There is a female to male 
preponderance in JSLE of around 4-5:1 (63), but this difference in gender is actually greater, 
at around 10:1 in adult-onset SLE. This predominance means that female hormones are 
generally considered to have an important role in the development of JSLE/SLE. A trial in 
females with SLE has shown those who received hormone replacement therapy to be at an 
increased risk of disease flare (64), but much of this apparent hormonal role is not 
understood. Nonetheless, the hypothesis does appear to be supported by JSLE 
epidemiology, with under-10s seeming to be at a ratio 1:1, females to males (65), 
suggesting a role for hormonal change in puberty. Both JSLE and adult-onset SLE have 
shown to be more common in non-Caucasians, especially affecting the Asian, Hispanic, 
African American, Afro-Caribbean, and Native American populations (63), with such groups 
affected with a five-times increased risk compared with Caucasians. JSLE is a disease of 
significant morbidity, owing mainly to the associated severe organ damage and drug 
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toxicity (66). There has been a dramatic increase in the survival of JSLE and SLE patients 
over the last decades, however the JSLE 10-year survival rate in the West may be less than 
90% (63). 
 
1.4.2 Pathogenesis 
 
Increased and dysregulated apoptosis (section 1.2.2) and the failure of apoptotic cell 
clearance (section 1.3.2) are believed to combine, generating a setting of accumulating 
apoptotic cells (51). A loss of self-tolerance develops (67), resulting in a mounted immune 
response against autoantigens. Antigen-presenting cells activate T lymphocytes (68), which 
in turn stimulate B lymphocytes. The B lymphocytes produce autoantibodies which, along 
with their autoantigens, form immune complexes that cause damage at the end-organs 
(36) (see Figure 1-6). Other effects include the generation of a pro-inflammatory 
environment, causing an activated immune response and aberrant cytokine production. 
The end stage of organ damage can actually serve to create and maintain a vicious circle by 
causing cell death, creating a potentially continuous source of autoantigens (51). Much 
remains unknown in the SLE disease process, but especially that of JSLE, in which there is a 
relative paucity of data. 
 
Figure 1-6 The pathogenesis of SLE (36) 
 
Prolonged exposure of autoantigens is thought to be the result of a combination of dysregulated (increased) 
apoptosis and the relative failure of apoptotic cell clearance. The autoantigens are then taken up by antigen-
presenting cells which activate T cells, and in turn B cells. The result of this is the production of autoantibodies 
which form immune complexes and result in end-organ damage. 
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1.4.3 Cytokines associated with SLE 
Particular consideration has also been given to tumour necrosis factor alpha (TNFα) and 
interferon alpha (IFNα), two cytokines particularly associated with SLE. 
 
1.4.3.1 Tumour necrosis factor alpha (TNFα) 
Tumour necrosis factor alpha (TNFα) is a pleiotropic cytokine with both pro-apoptotic and 
anti-apoptotic effects (depending on environmental context), that controls the activation 
and action of various cells and is an essential part of the inflammatory response (69). It is, 
in itself, a pyrogen, but can also precipitate sepsis by stimulating hepatocytes to manifest 
an acute phase response (through IL-1 and IL-6 secretion). The nature of TNFα’s action 
cannot be easily classified, however, and this is neatly illustrated in the SLE murine model 
and gives indication of the caution that should be afforded given its spectrum of effects. 
Contrasting studies have shown SLE-disease-esque NZB/W mice with reduced TNF-α levels, 
in which disease improved with TNFα administration (70), compared with the MRL/lpr/lpr 
mouse-line which has also demonstrated SLE-esque autoimmunity, but which has been 
found to have raised levels of TNFα in serum, with improvement from anti-TNFα therapy. 
To add to the difficulty of summarising the role of TNFα in SLE definitively, TNFα given to 
NZB/W mice in the later stages of disease actually expedited renal damage (71). Human 
studies in SLE have shown raised levels of TNFα compared with controls (72, 73) and raised 
levels of sTNFR1 and sTNFR2 (73) , soluble TNFα receptors shed from the cell surface in part 
due to stimulation by the cytokine. In JSLE, however, the opposite has been found with 
TNFα levels significantly lower in JSLE compared with controls (39). 
 
1.4.3.2 Interferon-alpha (IFNα) 
IFNα is another cytokine with multiple effects in immune regulation. It may be produced by 
a number of different cells, but it is the plasmacytoid dendritic cells which are considered 
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to be the primary secretors of circulating IFNα (74). Increased levels of the cytokine are 
often observed in SLE patients, perhaps pointing to its involvement in the immune 
dysregulation of SLE (75). The emergence of IFNα as a treatment for certain malignancies 
led to the observation that this therapeutic course may have been contributing to the 
development of SLE-associated autoantibodies and SLE disease manifestation in these 
patients (75). Further, a number of genes involved in the production of IFNα are associated 
with increased risk of SLE-onset (76). As if to link these points, studies have shown that 
families with SLE-sufferers tend to have higher serum IFNα levels than would healthy, 
unrelated individuals (77). IFNα levels have also shown to be associated with presence of 
cutaneous and renal disease, and with disease activity (78). IFNα-blocking therapy trials are 
currently underway, albeit remain at a stage of infancy (75). 
 
1.4.4 Clinical Features 
The clinical features of JSLE (and indeed SLE) can be protean and non-specific, especially at 
presentation when fever, weight loss and lymphadenopathy are commonest (66). This can 
present difficulty in diagnosis, especially in adolescents in whom symptoms such as fatigue, 
headaches, weight loss, mood swings and weakness could be considered part of the 
“normal” teenager. There may be presence of musculoskeletal problems such as arthritis or 
myalgia, dermatological involvement such as butterfly rash or generalised erythema, or 
renal signs such as proteinuria. Predominance of symptoms and signs in JSLE can differ 
from SLE; published data shows statistically increased incidence of renal (proteinuria, 
glomerulonephritis, urinary cellular casts), neurological (encephalopathy) and 
haematological (haemolytic anaemia) manifestations in JSLE (79). Less commonly, liver, 
cardiac and pulmonary systems can also be affected; reflecting a disease process which can 
affect any part of the body. JSLE patients have also been shown to have more active 
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disease at presentation, and suffer more disease flares and sustain more organ damage 
over time (80). 
 
Diagnosis can be made upon satisfaction of 4 of 11 features of the revised American 
College of Rheumatology criteria (81) (see Table 1-1), a combination of the associated 
clinical features and laboratory tests. Caution may be required, however, as evolving JSLE 
may not, at first, meet the diagnostic criteria and early, effective treatment can make a 
huge difference to disease course. 
Table 1-1 1997 Revision of the 1982 American College of Rheumatology SLE Diagnostic Criteria (73) 
 
The above table lists the 11 major criteria of which 4 or more must be satisfied for diagnosis of SLE. 
 
 
There are a number of aids designed to assess disease activity, such as the SLE Disease 
Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) tool, which 
may be especially useful in the case of disease flare. Organ damage can be assessed and 
monitored using the Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology (SLICCS/ACR) damage index (66). 
 
All organ systems need to be considered and screened throughout the course of JSLE, and 
the investigations undertaken should reflect these considerations accordingly. Useful blood 
tests include full blood count (anaemia, leukopenia, thrombocytopenia), urea and 
electrolytes, liver function tests (hypoalbuminaemia, raised transaminases), CRP (C-reactive 
protein) and ESR (erythrocyte sedimentation rate) (raised inflammatory markers), C3 and 
C4 (often reduced) and C1q levels and anti-C1q antibodies, among others. 
 
Malar rash 
Discoid rash 
Photosensitivity 
Oral or nasal ulcerations 
Nephritis 
   Proteinuria > 0.5g/day 
   Cellular casts 
 
Non-erosive arthritis 
Encephalopathy 
   Seizures 
   Psychosis 
Pleuritis or Pericarditis 
Cytopenia 
 
Positive (+ve) Immunoserology 
   Antibodies to dsDNA 
   Antibodies to Sm nuclear antigen 
   +ve finding of antiphospholipid antibodies or 
   Lupus anti-coagulant or  
   False +ve serologic test for syphilis for >6 months 
Positive antinuclear antibody test 
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Autoantibodies can be tested for, such as anti-double-stranded DNA, anti-Ro, La and Sm. 
These autoantibodies, and others, have also been implicated in the SLE disease 
pathogenesis (82). 
 
1.4.5 Management 
The management of JSLE requires a holistic multi-disciplinary approach in order to best 
support the development of the patient; physically, psychologically and socially. The long-
term implications of disease and therapeutics with respect to fertility, cardiovascular 
involvement and risk of malignancy require careful consideration (66). 
 
Similarly, the need to provide sufficient treatment to suppress the disease process and 
reduce organ damage is tempered by the immunosuppressive risks of infection and 
malignancy. Treatment strategy can be divided into that of induction and maintenance 
therapies. 
 
Induction aims to induce remission of the disease flare, through aggressive treatment to 
endeavour to prevent organ damage. Corticosteroids are the mainstay of induction, and in 
mild disease, can be given orally, but in moderate or severe disease, intravenous 
methylprednisolone should be given in pulses, followed by high doses of oral prednisolone 
(83). Previously, intravenous cyclophosphamide pulses were part of induction therapy (and 
still can be), though mycophenolate mofetil is now more commonly used with evidence 
showing it to be at least as effective as cyclophosphamide for induction (83), and 
azathioprine is another alternative therapy. 
 
Maintenance therapy may also vary depending upon the JSLE disease severity. 
Hydroxychloroquine should be given unless contraindicated as it reduces the long-term risk 
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of flares, is disease-modifying, steroid-sparing, and lipid-lowering (84). Originally an 
antimalarial, its beneficial effects in SLE appear to be attributable to its reported inhibitory 
action on the toll-like receptor 9 family of receptors (85). Usually either mycophenolate 
mofetil or azathioprine will be used in maintenance, in preference to cyclophosphamide 
which is associated with more severe infections – recent studies have suggested infection is 
the main cause of death in JSLE (83). Oral prednisolone should be used in conjunction, and 
gradually withdrawn as disease permits. The regime should be continued for several years 
to achieve persistent remission, especially crucial during childhood development (66). In 
the severe stages and manifestations, cyclophosphamide may need to be used but its use is 
generally constrained to such circumstances (86). Unfortunately, these treatment regimens 
are not the result of large randomised controlled trials but of a combination of adult 
studies, small paediatric cohort studies and clinical experience, and this accounts for the 
variances in pharmacological management across the country, and indeed the world (83). 
There are, however, a number of new therapies being developed and tested, the majority 
of which are aimed at B-lymphocyte depletion. Belimumab is one such drug, a human 
monoclonal antibody aimed at inhibition of B-lymphocyte stimulator/B-lymphocyte 
activating factor, which has offered good results in trials to date (87). Recently published 
data from phase 3 trials has continued this trend, with increased odds of positive response 
to treatment than with standard therapies plus placebo (88).  Rituximab has been used in 
JSLE and associated nephritis to reported good effect, albeit with lingering doubts over its 
safety profile especially in repeated doses (83). A monoclonal antibody that targets the B 
lymphocyte transmembrane protein CD20, it causes depletion of these cells by inducing 
apoptosis as well as through cytotoxicity (89). Ocrelizumab is a fully humanised anti-CD20 
monoclonal antibody (90) which thereby avoids some of the concerns surrounding 
rituximab use in SLE, such as human anti-chimeric antibodies and virus-induced progressive 
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multifocal leukoencephalopathy (83). There is also a humanised anti-CD22 drug, 
epratuzumab, well-tolerated in adult-onset SLE with good evidence of clinical benefit (91). 
 
  
33 
 
1.5 Receptors associated with apoptotic cell clearance 
There are a number of receptors that have been implicated in the process of apoptotic cell 
clearance. Several of these receptors are demonstrated pictorially in Figure 1-7, a 
hypothetical phagocyte encircling an apoptosing cell. Some of the receptors shown are 
associated with the “find me” process, whilst others are associated with the “eat me” 
process. The sheer number of receptors and the differences in purpose and function 
highlights the difficulty of attempting to investigate them as potential markers of 
phagocytosis. However, a few of these receptors have been reviewed in more detail based 
on their relative importance based upon the currently available literature. 
 
 
Figure 1-7 A “superphagocyte” engulfing an apoptotic cell (92) 
 
The figure outlines the various receptors associated with both the apoptosing cell, and the phagocyte 
responsible for its removal. β2GPI-R, β2-glycoprotein I receptor; ABCA1, ATP-binding cassette transporter 1; 
aCHO, altered carbohydrate; ASGPR, asialoglycoprotein receptor; BAI-1, brainspecific angiogenesis inhibitor 1; 
CRT, calreticulin; dCD31, disabled CD31; MFG, milk-fat globule EGF-8; OxLls, oxidized LDL-like site; OxPL, 
oxidized phospholipid; SHPS-1, Src homology 2 domain-bearing protein tyrosine phosphatase substrate- 1; TBS, 
TSP-binding site; Tim 1,3,4, T cell Ig and mucin domain-containing molecule 1, 3, or 4. 
 
 
1.5.1.1 MER and αvβ5 Integrin 
 
MER is a cell-membrane bound receptor tyrosine kinase, part of the TYRO3/AXL/MER 
receptor family (TAM) first identified in 1991 (93, 94). It is such-named for where it can be 
found; expressed by monocytes, and in epithelial and reproductive tissue. The principal 
ligand for MER is considered to be growth arrest-specific protein 6 (Gas6), common to all 3 
members of this receptor family, but MER can also bind to the structurally-similar protein 
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S.  It is through their common ~60 amino acid Gla domains that give Gas6 and protein S the 
capability to in turn bind PS (95) (exposed by apoptosing cells). Interestingly, Gas6 is able to 
bind-to and activate all three receptors, but with extremely variable affinities, with MER 
actually showing the least affinity to Gas6 of the three TAM receptors (comparatively lower 
by 3-10 fold) (96). Upon the binding of Gas6 or protein S to the tyrosine kinase receptor, 
receptor dimerization and activation of the kinase occurs, resulting in the recruitment, 
phosphorylation and activation of multiple downstream signalling proteins, modifying cell 
physiology (97). It was initially shown, in murine studies, that reduced MER expression 
resulted in reduced apoptotic cell clearance and the manifestation of SLE-like autoimmune 
disease (98), with just over 50% of MER-knockout mice found to have serum positive for 
anti-DNA antibodies (compared with 0% of wild-type mice). It was described, by Scott et al, 
to appear critical for the clearance of apoptotic cells. Macrophages from the MER knockout 
mice were 83-94% less efficient in apoptotic cell phagocytosis than macrophages from wild-
type mice. The authors also demonstrated that macrophages from mice containing a 
kinase-dead version of MER were able to bind to, but not able to internalise apoptotic cells. 
Similarly, research has also shown anti-MER antibodies to prevent internalisation but not 
binding of apoptotic cells (99). Investigation in the murine model has also compared the 
capacity of this family of receptors for apoptotic cell clearance, elegantly demonstrating 
that MER knock-out reduced phagocytic capacity by a much greater extent than AXL or 
TYRO3. The impression of the MER’s role as an important receptor for apoptotic cell 
clearance has been built upon and is now widely-held. 
 
Recent work by a research group from the University of Pennsylvania has served to further 
increase the MER knowledgebase. Their findings suggest that MER also has a key role in the 
activation of self-reactive B cells in autoimmunity (100). Mice tangible body macrophages 
from the germinal centres were found to express MER, and in their MER knockout mice, 
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they observed greater B lymphocyte populations and greater antibody responses (101). 
They also report greater B lymphocyte populations in splenic marginal zone of their 
knockout mice, with some producing anti-dsDNA (102), and that these findings support the 
suggested role of MER in the regulation of cytokine secretion and antigen presentation. 
Research published by Galvan et al has linked MER expression to C1q, with results 
suggesting C1q stimulates expression of MER and Gas6 (103). 
 
Investigation of the role of glucocorticoids, commonly used for the treatment of SLE and 
JSLE, in apoptotic cell clearance has suggested a novel pharmacological effect of this drug 
family (104). Their findings indicate that monocyte-derived macrophages incubated with 
dexamethasone show increased phagocytosis of early apoptotic cells than those cultured 
without glucocorticoid. The apoptosing cells they used, neutrophils, were specific to 
protein S, so they suggest that glucocorticoid stimulates associated-recognition. Their 
results with glucocorticoid-treated macrophages exposed to anti-MER antibodies, which 
appeared to lose the benefit attained from dexamethasone, suggest that it is MER in 
particular that is aided in the presence of glucocorticoids. This could indicate a mechanistic 
basis for the efficacy of steroid treatment in JSLE. 
 
Cleavage of the MER receptor from the cell surface gives rise to its recognised soluble form 
(sMER), formed by cleavage caused by metalloproteinase exposure. This process has been 
observed to be expedited in response to the stimuli lipopolysaccharide (LPS) and the 
protein kinase C activator, Phorbol 12-Myristate 13-Acetate (PMA) (105). PMA activates 
protein kinase C and in doing so has been observed to rapidly induce apoptosis (106). LPS 
has also been shown to inhibit the phagocytosis of apoptotic neutrophils through TNFα 
induction and Gas6 suppression (107). The cleavage site has been recently observed, at 
proline 485 in mouse macrophages (108). Also described by the authors is the involvement, 
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specifically, of the ADAM17 metalloproteinase, demonstrating that LPS-induced cleavage 
required both ADAM17 and disintegrin. Further, they identify the importance of TLR4 
(which detects LPS), through TIR-domain-containing adapter-inducing interferon-β (TRIF) 
adaptor signalling for the cleavage of MER. The soluble form of MER can therefore bind 
Gas6 (or protein S), blocking activation of MER through the occupation of this ligand, and 
has been found to thereby inhibit macrophage clearance of apoptotic cells (105). A recent 
study has shown increased sMER levels in SLE plasma compared with HC, related to both 
disease activity and SLE nephritis (109). The authors hypothesise that the apoptotic debris 
present in SLE may be responsible for increased MER expression and shedding. 
 
This tyrosine kinase receptor appeared to be an important receptor for apoptotic cell 
clearance and with potential significance with regards to autoimmunity. Further, its cleaved 
form, sMER, has been shown to negatively impact upon the in vitro phagocytosis of 
apoptotic cells. 
 
1.5.1.2 αvβ5 integrin 
 
αvβ5 is an integrin most closely associated with its cooperation with the AXL/MER/TYRO3 
tyrosine kinase family of receptors (110). There is significant synergy shared between 
receptors; post-translational modification of receptors and recruitment of signal proteins, 
recruitment of receptors and alterations in ligand-binding affinities (29). It has been shown 
to bind to PS through the ligand milk fat globule-EGF factor 8 protein (MFG-E8) (111), which 
is itself an opsonin for phagocytosis secreted by macrophages and dendritic cells. It is 
postulated that the role of αvβ5 is to bind apoptotic cells (via MFG-E8), increasing the 
chance of contact and binding of the apoptotic cell to the MER receptor, to internalise the 
apoptotic cell (29) (see Figure 1-8). 
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Figure 1-8 MER and αvβ5 integrin apoptotic cell interaction (29) 
 
The figure illustrates the interaction and cooperation between the MER (labelled Mer-TK on diagram) and αvβ5 
integrin receptors in the uptake of apoptotic cells. αvβ5 is thought to be important for tethering cells, and MER 
for the internalisation process. 
 
 
1.5.1.3 Scavenger Receptor Class B – CD36 & αvβ3 integrin 
The involvement of CD36, and indeed of scavenger receptors themselves, in apoptotic cell 
clearance was first outlined in 1991, in the recognition of apoptosing neutrophils (112). 
These CD36 receptors were shown to act in collaboration with the avβ3 vitronectin 
(CD51/61) receptors, binding either thrombospondin (113) or milk fat globule-EGF factor 8 
(MFG-E8) (114), with either of these ligands in-turn bridging to the apoptotic cell (115). 
CD36 has also been shown to induce an anti-inflammatory response in monocytes with 
ligation increasing IL-10 whilst decreasing TNF-α secretion (116), but there appears to be an 
element of variability to the receptor, with this shown not to be the case in the 
macrophage (117). CD36 expression by monocytes has been investigated in SLE, but the 
authors report not-significant difference between those of SLE and those of controls (118). 
This has been corroborated by Yassin et al (119) through similar methods. It has, however, 
been shown that thrombospondin and avβ3 antibodies inhibited macrophage phagocytosis 
of apoptotic cells (120), suggesting a role for these synergistic receptors that is currently 
proving elusive. The avβ3 vitronectin may actually have capacity for multi-function in 
apoptotic cell clearance, with a recent study presenting findings showing it to be essential 
in the internalisation of an apoptotic cell, in cooperation with TIM4 as a tethering receptor 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
Wu Y, Tibrewal N, Birge RB. Phosphatidylserine recognition by 
phagocytes: a view to a kill. Trends in cell biology. 2006;16(4):189-97. 
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(121). As such, the CD36 receptor was targeted for investigation due to its supposed 
significance as a receptor for apoptotic cell phagocytosis. 
 
1.5.1.4 Complement Receptors CR3 & 4 
It has been shown that exposure of PS is involved in complement activation and results in 
C3bi coating of these apoptotic cells. The macrophage receptors for C3bi, CR3 
(CD11b/CD18) and CR4 have been shown to be generally more efficient in apoptotic cell 
uptake than other receptors (122).  Complement component C3 is fundamental to 
opsonisation (123). Complement is a hugely important part of the immune system and 
encompasses a number of different proteins with a number of different roles. Complement 
deficiency is often observed in patients with SLE and the levels are used as a biomarker. It 
has been observed that a fall in complement levels precedes an SLE disease flare. C1q 
deficiency is strongly associated with SLE-onset, with more than 90% of C1q-deficient cases 
developing SLE (124). Around 20% of C2-deficient cases develop SLE (125). A study 
categorised JSLE patients into three groups, according to C4 protein levels (126). One group 
had persistently low C4 levels, and a generally mild disease activity. The second group had 
fluctuating C4 concentrations and were noted to follow a similarly fluctuant disease course. 
The third group had generally-high levels, with the incidence of low levels coinciding with 
disease flares. So complement can offer predictive value for disease severity and course, 
and is important in augmenting phagocytosis. CR3 was selected on the basis of its 
association with apoptotic cell clearance but also as complement deficiency is often 
observed in SLE and JSLE patients. It is also, however, a more general phagocytic marker as 
also important for pathogen uptake. 
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1.6 Summary 
JSLE is a rare but often severe multi-systemic autoimmune disease, diagnosed upon the 
satisfaction of four or more of eleven diagnostic criteria. It is often more severe than adult-
onset SLE, but there remains a relative dearth of research into JSLE. Drugs such as 
corticosteroids and hydroxychloroquine have dramatically improved symptoms, disease 
activity and overall survival, but there are no curative treatments and there remains a 
deficiency of therapeutics targeted at the underlying pathophysiology. The pathogenesis of 
SLE is believed to be triggered by autoantigens originating from dying cells. The 
combination of dysregulated cell apoptosis and the failure of clearance of these cells by 
phagocytosis are thought to result in the exposure of autoantigens. The loss of self-
tolerance to these autoantigens sees a mounted immune response against them, with the 
result of which is the end-organ damage associated with JSLE pathology. A number of 
receptors are associated with the process of apoptotic cell clearance, such as MER, CD36 
and CR3. 
Hypothesis 
Monocytes and macrophages are key phagocytes and their function in JSLE may be 
impaired, resulting in the failure of apoptotic cell clearance. This failure may result in the 
exposure of autoantigens against which an immune response is mounted in JSLE. The study 
hypothesis is that expression of receptors MER, CD36 and CR3 differ in JSLE monocytes and 
macrophages compared with HC. 
Aim 
To analyse the expression of receptors MER, CD36 and CR3 in JSLE monocytes and 
macrophages compared with HC. 
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Objectives 
 To measure the mRNA expression of receptors MER, CD36 and CR3 in JSLE 
monocytes and macrophages compared with HC monocytes and macrophages. 
 To measure the concentration of cleaved MER, sMER, in JSLE plasma, compared 
with plasma from JIA and HC patients. 
 To compare the phagocytic function of monocytes in JSLE plasma with HC plasma. 
 To measure change in expression of CD36, MER and CR3, and loss of sMER, after 
exposure of monocytes to LPS, IFNα, TNFα, and apoptotic neutrophils. 
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2 Methods 
2.1 Patients 
Patients were recruited to this study as part of their participation in the UK JSLE Cohort 
Study (127), a study with approval from the Liverpool Paediatric Research Ethics 
Committee (Appendix 1: Research Ethics Approval). Written, informed (Appendix 2: 
Information sheets for the UK Juvenile Lupus Cohort Study and Repository) consent 
(Appendix 3: Patient’s consent form for the UK Juvenile Lupus Cohort Study and 
Repository) was sought from all participating patients and their parent or guardian. JSLE 
patients fulfilled at least 4 of the 11 revised ACR criteria for the diagnosis of SLE before the 
age of 17 years. Juvenile idiopathic arthritis (JIA) patients, diagnosed according to the 
modified International League of Associations for Rheumatology for JIA (128), were 
included as paediatric inflammatory controls. Paediatric “healthy” controls were recruited 
from those attending hospital for non-inflammatory surgery. In practice, these included 
procedures such as a dental extraction or pinnaplasty. HC were excluded from recruitment 
in the case of known inflammatory or autoimmunity disorder, presence of inter-current 
infection or current drug therapeutic regime. All patients were recruited from outpatient 
clinics and inpatient wards at Alder Hey Children’s NHS Foundation Trust in Liverpool. 
Sample collection occurred upon clinic attendance at the time of blood requests for disease 
monitoring. Around 10 mLs of blood was collected with 1-2 mLs for serum and the 
remaining volume for plasma and cells. Samples were immediately transferred to the 
laboratory and processed according to protocol. All study samples were anonymised 
following collection and the investigator was blinded to the corresponding clinical and 
laboratory data until experiment completion.  
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2.2 Blood Sample Processing 
Blood samples of JSLE, JIA and paediatric and adult HC samples were received and 
processed in the laboratory. Serum (without anticoagulant) and plasma (heparinised) 
bottles were used to collect blood; with serum bottles used to process serum alone, and 
plasma bottles used to process peripheral blood mononuclear cells (PBMCs), neutrophils 
and plasma. Processing was commenced within an hour of blood collection. All processing 
was conducted within the sterile field of a tissue culture hood. 
 
Blood (plasma) was layered above an equal volume of Polymorphprep (Axis-Shield PoC AS, 
Norway) and centrifuged at 530 xg for 30 minutes at room temperature with the brake 
turned off (Figure 2-1). Polymorphprep needs to be used at around 20oC to allow loss of 
water from red blood cells to the hyperosmotic medium to occur. If the brake is used to 
decelerate the rotor, the cell bands can cross-contaminate and the erythrocytes may not 
settle at the bottom of the tube. Alternatively, if a patient’s blood was known to centrifuge 
poorly upon Polymorphprep (e.g. if white blood cells previously failed to separate from red 
blood cells), Histopaque-1077 (SIGMA-ALDRICH, UK) wash used in substitution of 
Polymorphprep. 
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Figure 2-1 Whole blood, before and after centrifugation  
 
Falcon tube with blood layered over Polymorphprep, before (a) centrifugation at 530 xg for 30 minutes at room 
temperature, and after (b) as the PBMCs and neutrophils separate to form two distinct layers. 
 
 
A sterile Pasteur pipette was used to transfer PBMCs and neutrophils into separate falcon 
tubes. These were then washed with RPMI-1640 (LONZA, Belgium) and subsequently 
centrifuged at 670xg for 10 minutes. The medium was removed and the newly-formed 
pellets were resuspended in lysis buffer consisting of 9 mLs of Ammonium Chloride 1% and 
1 mL RPMI-1640. The solutions lysed for 3 minutes, then centrifuged at 670xg for 5 
minutes. By this process, any present red blood cells were lysed leaving a purer remaining 
population of cells. Medium was again removed and the cell pellets re-suspended. 
 
a b 
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2.2.1 Storage of PBMCs 
1 mL of freezing media (90% Foetal Calf Serum (FCS) [SIGMA-ALDRICH, UK) + 10% Dimethyl 
sulphoxide (DMSO) [SIGMA-ALDRICH, UK]) was added and mixed with PBMCs, transferred 
to an insulated cryovial and stored at -70oC for 24 hours, then transferred to storage in 
liquid nitrogen. 
 
2.3 Monocyte Separation 
Processed blood samples were used to separate the CD14+ monocyte cell fraction, which 
was then either used, stored at this point, or cultured into macrophages. The CD14+ cell 
separation was performed according to manufacturer’s instructions; MACS Miltenyi Biotec 
– CD14 MicroBeads Protocol. 
 
Continuing from section 2.2 (following centrifugation at 670xg for 10 minutes) RPMI-1640 
was removed leaving the PBMC pellet, and a cell count was performed using a Neubauer 
haemocytometer (Superior Marienfeld, Germany). During the cell count, cells were re-
pelleted by centrifugation at 670xg for 5 minutes. 
 
Buffer was prepared comprising sterile phosphate-buffered saline (PBS) pH 7.2 with 2mM 
ethylenediaminetetraacetic acid (EDTA) and 0.5% FCS (buffer was kept on ice when not in 
use). PBS and EDTA solution was passed through a Minisart-Plus filter (SIGMA-ALDRICH, 
UK) to sterilise, prior to addition of FCS. 
 
RPMI-1640 was removed from sample before adding 80 µl of buffer and 20 µl CD14 
MicroBeads (MACS Miltenyi Biotec, Germany) per 107 i.e. 10 million cells, and this solution 
was incubated at 2-8oC for 15 minutes. The MicroBeads magnetically label the CD14+ cells. 
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The cells were washed in 1-2 mLs of buffer and centrifuged at 670xg for 5 minutes. A 
magnetic unit was set-up, with MiniMACS Separator (MACS Miltenyi Biotec, Germany) and 
MACS Separation Column (MACS Miltenyi Biotec, Germany) (Figure 2-2). First, the column 
filter was wetted with 0.5 mLs of buffer, collected into a falcon tube (for CD14- cells), and 
once filtration was finished, centrifuged PBMCs were re-suspended in 0.5 mLs of buffer and 
transferred onto the column. 
 
Figure 2-2 Apparatus setup for cell separation 
 
Setup for CD14 separation, with the MiniMACS Separator and MiniMACS Separation Column set over a falcon 
tube (to collect CD14- cells). 
 
 
Another 0.5 mLs of buffer was added to PBMC falcon tube to capture any remaining cells 
and transferred to column, after which a further 0.5 mLs of buffer was added directly to the 
column, and one final 0.5 mLs of buffer. Once this last quantity of buffer had passed 
through the magnetic column, the column was transferred onto a clean falcon tube. 1 mL 
of buffer was added to the column, and cells were flushed through the column by applying 
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the plunger to the column. At this stage, the CD14+ cells which had been magnetised to the 
column were expelled into the tube with the buffer. 
 
2.3.1 Macrophage culture 
 
CD14+ cells were washed through centrifugation at 670xg for 5 minutes, resuspended in 
RPMI, and cell count was performed using a haemocytometer. Cells were cultured at a 
concentration of 0.5x106 cells in 1 mL of medium per well, in a Nunclon Δ (delta) surface 24 
well plate (NUNC, Denmark). 
 
The buffer was removed and the CD14+ cells were resuspended in a culture medium 
comprising: 
 RPMI (LONZA, Belgium) 
 10% FCS (SIGMA-ALDRICH, UK) 
 1% Penicillin Streptomycin (10 mg/mL) (SIGMA-ALDRICH, UK) 
 Macrophage colony-stimulating factor (M-CSF) (at a concentration of 50 ng/mL) 
 
Each 1 mL of CD14+ cells in culture medium was transferred into an individual well in the 24 
well plate, and the plate was incubated at 37oC for 6 days.  
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2.4 RNA Extraction 
Culture medium extracted from wells containing monocytes/macrophages, and 350µl of 
Lysis BME BME (Buffer RLT (QIAGEN, Germany) with 1% 2-mercaptoethanol [SIGMA-
ALDRICH, UK]) pipetted into wells and transferred to QIAshredder (QIAGEN, Germany). The 
QIAshredder was centrifuged at 7527 xg for 2 minutes (at room temperature). The filter 
was discarded, and 350 µl of 70% ethanol was added to the collection tube, mixed, and all 
contents were transferred to a RNeasy Mini Spin Column (QIAGEN, Germany) and 
centrifuged at 7527 xg for 15-20 seconds. 
 
Liquid was discarded from collection tube and 700 µl of Buffer RW1 (QIAGEN, Germany) 
added to the column, then centrifuged at 7527 xg for 15-20 seconds. The liquid was 
discarded and 500 µl of Buffer RPE (QIAGEN, Germany) was added to the column, with this 
process repeated twice - the first centrifuge for 15-20 seconds and the second for 2 
minutes. The filter was then dried by transferring it to a fresh collection tube and 
centrifuged at 7527 xg for 2 minutes. 
 
The filter was transferred onto an eppendorf, 40 µl of RNase-free water (QIAGEN, 
Germany) was added, and it was left to soak for 30 seconds then centrifuged at 7527 xg for 
1 minute. The filter was discarded, the eppendorf (now containing RNA) was retained and 
stored at -70oC. 
 
2.4.1 RNA Assessment 
RNA was assessed for quantity and quality using NanoDrop ND-1000 Spectrophotometer 
(Thermo SCIENTIFIC, USA) and accompanying computer software. Quantity (ng/mL) was 
measured and quality was assessed according to the 260/280 value, where a range of 1.8-
2.2 was deemed of sufficient quality to be utilised for investigation.  
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2.5 Quantitative Polymerase Chain Reaction (qPCR) 
2.5.1 The principles of PCR 
Polymerase Chain Reaction (PCR) is a technique which sees short sequences of DNA 
amplified by repeated cycles of replication. By increasing and decreasing the temperature 
DNA was exposed to, it was possible to form duplicates of DNA sequences. The process can 
be summarised into the following basic steps: 
1. Denaturation – the double-stranded DNA helix is heated to 94-98oC, causing it to 
melt apart into two separate strands. 
2. Annealing – the reaction is cooled to 45-65oC, enabling single-stranded primers to 
“anneal” to the now single-stranded DNA template. At this point, DNA polymerase 
attaches to the primed template and begins to attach complementary nucleotides. 
3. Extension – the temperature is increased to 65-75oC, which enables polymerase to 
function in an optimised environment, extending the primer sequence through 
incorporation of complementary nucleotides, yielding a new double-stranded DNA 
unit. So from each double-stranded DNA helix that is started with, two new DNA 
helices are formed. 
 
This process can then be repeated for any number of cycles.  
 
2.5.2 The principles of real-time quantitative PCR (qPCR) 
Quantitative PCR (qPCR) was a particularly important extension of the PCR principle that 
enabled measurement of gene expression. By converting RNA to cDNA through reverse-
transcription, the cDNA could be subsequently amplified by PCR. This has in turn been 
improved upon by real-time qPCR, in which amplification of specific nucleic acid sequences 
is followed by quantitation of the amounts of DNA present after each cycle (129). The 
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advantages of real-time qPCR over semi-quantitative PCR are reduced non-specific 
amplification, greater dynamic range and reduced RNA requirement (130). 
 
Real-time qPCR allows quantitative measurement of the products during the course of the 
reaction. It is performed in a thermocycler that can measure the level of a fluorescent 
detector molecule, and this these measurements are carried out after every cycle. The 
fluorescence of such molecules increases in proportion to the increasing amplification of 
DNA. The use of these molecules reduces the post-processing steps and minimises 
experimental error (130). Commonly used for qPCR include probe sequences that fluoresce 
upon hydrolysis (e.g. TaqMan) or hybridisation (e.g. LightCycler), fluorescent hairpins, or 
intercalating dyes (e.g. SYBR Green) (130). 
 
For the purposes of the experiments conducted, SYBR Green was used. SYBR Green 
fluoresces upon binding to double-stranded DNA, and does so in a dose-dependent manner 
(see Figure 2-3), according to the amount of double-stranded DNA present (131). The 
advantages of SYBR Green are that it is sensitive, relatively inexpensive and simple to use. 
The main disadvantage of SYBR Green is that as it is unselective in binding double-stranded 
DNA, it can also bind primer-dimers – where primers bind to one-another – or other 
reaction products, which may confound results. However, such primer-dimers can be 
detected through the dissociation curve, in which they can be observed to have a lower 
temperature of dissociation than target DNA because of their shorter sequences (see 
2.5.4). 
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Figure 2-3 SYBR Green fluorescence in response to double stranded DNA 
 
SYBR Green intercalating dye; showing the direct correlation between amount of double-stranded DNA present 
and fluorescence: (a) less double stranded DNA and therefore less fluorescence and (b) more double stranded 
DNA and fluorescence (adapted from (132). 
 
 
In order that we may realise the full potential of real time qPCR, it is important that good 
controls are used that will normalise the results, accounting for differences in the quantity 
and quality of starting material and in reaction efficiency (130). This is achieved by 
reference or “housekeeping” genes, selected on the basis that their expression is similar in 
all samples used, resistant to environmental conditions, and that they go through PCR with 
the same kinetics as the target gene (133) (section 2.6.4). 
 
A number of graphs produced at the end of the real-time qPCR process give indication as to 
the reliability of results gathered. 
 
2.5.3 Amplification Plot 
The Amplification Plot graphs number of cycles on the x-axis (n) against the detected 
fluorescence on the y-axis (dR): Figure 2-4 is one such example. The first part of the 
Amplification Plot is the “exponential” phase, during which every cycle should mark 
doubling of PCR product as there should be no limiting factors for the reaction. Initially, 
growth is difficult to detect because the amount of product is small and fluorescence low, 
but it becomes apparent as the fluorescence increases and passes through the threshold – 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
SIGMA-ALDRICH. SYBR Green based qPCR technical animation. SIGMA-
ALDRICH; 2012 [cited 2012 8 August]; Available from: 
http://www.sigmaaldrich.com/sigma-aldrich/areas-of-interest/life-
science/molecular-biology/pcr/quantitative-pcr/sybr-green-based-
qpcr/syber-green-animation.html. 
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the fractional cycle number (CT). This is the point at which the emitted fluorescence is 
greater than the background noise. During the “linear” phase, product is continually 
formed but reaction elements deplete and efficiency decreases. The reaction then enters 
the plateau phase, as enzymatic activity decreases and substrates limit product formation. 
 
Figure 2-4 Example of a qPCR amplification plot 
 
The graph illustrates the three stages of qPCR: exponential, linear and plateau. Also shown is the threshold, 
representative of the fractional cycle number (CT). 
 
 
2.5.4 Dissociation Curve 
The dissociation or melting curve charts the temperature of dissociation of PCR products 
(see Figure 2-5). Temperature is increased in small increments, and fluorescence measured. 
At the melting point, the double-stranded DNA will dissociate and fluorescence will 
decrease. Temperature (oC, x-axis) is plotted against the rate of change of fluorescence (-
RI(T), y-axis), and the peak change will occur at the melting point. Performed at the end of 
the PCR cycles, it means we should be able to observe if there have been any problems 
with the PCR, for example primer-dimers, mispriming, or contamination. As mentioned 
earlier, as these other causes will produce smaller products, they will have a lower 
dissociation temperature, and so produce a distinct peak or distinct peaks. 
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Figure 2-5 Normal Dissociation Curve 
 
This dissociation curve has a uniform peak of negative change of fluorescence at around 81oC indicating the 
presence of only one product. 
 
 
Figure 2-6 shows an abnormal dissociation curve, with a peak of certain samples at >80oC, 
but another, more consistent peak at around 73oC, so a lower-than-expected dissociation 
demonstrating the presence of more than one product, and suggesting the presence of 
primer-dimers. 
 
Figure 2-6 Abnormal Dissociation Curve 
 
This dissociation curve has a second peak at a lower temperature indicating the potential occurance of primer-
dimerisation. 
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2.5.5 Standard Curve 
The Standard Curve charts the initial quantity (number of copies, x-axis) against the CT;
 the 
point at which the fluorescence crosses the threshold (dR, y-axis) (see 2.5.3). In the 
experiments conducted, a 5-point standard curve was used in triplicate, with standards 
from neat to 1 in 20 dilution, and these 5 points are used for the linear graph. The resultant 
linear plot is used to work out the amount of DNA initially present in samples based on the 
measured CT values (see  
Figure 2-7). The consistency of these results may be observed by testing in triplicate. 
 
 
Figure 2-7 An example qPCR Standard Curve 
 
The standard curve has a strong R2 value (close to 1.0), indicating good reliability. 
 
 
The Standard Curve should have a good efficiency (as close to 100% as possible), and a R2 
value close to 1.0 so the results may be accepted. 
 
2.6 Reverse Transcription and Real-time qPCR Protocols 
2.6.1 Reverse Transcription 
RNA (100 ng/μl) was added to RNase-free water (QIAGEN) to a final volume of 14 μl and 1 
µl of random primers added, and this mixture was heated at 70oC for 5 minutes. A master 
mix of reverse transcription was made up consisting of the following, per RNA sample: 5 µl 
MMLV Reverse Transcriptase 5X Buffer (Promega, USA), 1.25 µl Nucleotides (Promega, 
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USA), 0.5 µl RNasin RNase inhibitor (Promega, USA), 1 µl MMLV Reverse Transcriptase and 
2.25 µl RNase-free water (QIAGEN). 
The total 10 µl of master mix was added to each sample of RNA, and samples were heated 
at 42oC for 1 hour. The cDNA was then diluted to a 1 in 4 solution, and stored at -20oC until 
required. 
 
2.6.2 Real-time qPCR 
Real-time qPCR was carried out using the Mx3005P instrument and MxPro v4.0 software 
(Strategene, Agilent Technologies, UK). The template was first devised, consisting of a non-
template control (RNase-free water)), standards and the samples, all of which were tested 
in triplicate. To produce the experiment standards, serial dilutions of the pooled standard 
were made, resulting in 5 standards of varying concentrations (neat, 1 in 2, 1 in 5, 1 in 10, 
and 1 in 20). 
 
With template samples ready, these were stored on ice whilst a qPCR master mix was 
made up. This consisted of the following quantities, per well: 0.75 µl Forward Primer 
(Eurofins MWG Operon, Germany), 0.75 µl Reverse Primer (Eurofins MWG Operon, 
Germany), 10 µl SYBR Green ([PerfeCTa SYBR Green FastMix Low Rox] Quanta Biosciences, 
USA) – and 3.5 µl RNase-free water (QIAGEN). 15 µl of master mix was then aliquoted into 
each well, followed by 5µl of appropriate sample. The wells were sealed with caps and 
centrifuged for 20seconds at 1200rpm. The following thermal profile was used for real-time 
qPCR. Figure 2-8 (see below) shows the thermal profiled used for the conducted qPCR 
experiments. The reasons for the temperatures have been largely explained previously (see 
2.5.1), with Segment 2 representing a 40-cycle period of denaturation and annealing, 
followed by Segment 3 testing for product dissociation. 
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Figure 2-8 Thermal Profile utilised for undertaken qPCR experiments 
 
2.6.3 Data Analysis 
Analysis of real-time qPCR data is carried out by one of two methods: absolute levels or 
relative levels. 
Absolute uses the number of copies of RNA. For this, results have been converted into 
relative expression ratios by: 
 
                           
                
              
 
 
Where relative quantitation could be carried out, the following formula has been utilised. 
 
                   
 
This approach is dependent on the assumptions of 100% efficiency, i.e. doubled product 
every cycle, and that the reference gene is expressed at a constant level across samples. 
The resultant fold change is positive, if greater than 1, and negative if between 0 and 1 (in 
this case, the inverse [i.e. 
 
 
] is taken to give fold change reduction). 
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2.6.4 Reference Gene Selection 
Reference genes, as discussed in section 2.5.2, are used to normalise data; in order that we 
may correct for any differences in starting materials (134). So the resultant quantity found 
for any gene of interest is compared against the quantity of the selected reference (or 
“housekeeping”) gene. Two reference genes were tested for suitability, beta-2-
microglobulin (β2M) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). β2M is a 
small polypeptide associated with the major histocompatibility complex (MHC) class 1 
heavy chain, found on the surface of almost all nucleated cells (135). GAPDH is an enzyme 
primarily concerned with the process of glycolysis, commonly used as a reference gene 
(136). Upon testing with cDNA produced from adult HC macrophage RNA, both genes 
appeared to be consistently expressed, with β2M appearing superior. Combined with 
evidence in the literature suggesting GAPDH expression varies in certain experimental 
settings (137) and can even vary within a cell subpopulation (138), and a study investigating 
reference gene expression in alveolar macrophages finding it to be unstably expressed 
(139), β2M was selected as the reference gene to use for the real-time qPCR undertaken. 
 
2.6.5 Primers 
Table 2-1 lists the primers used in the real-time qPCR experiments conducted and the 
forward and reverse nucleotide sequences. 
Table 2-1 Primer Sequences used for real-time qPCR 
 
Primer Forward Reverse 
β2M 5’-TGCCTGCCGTGTGAACCATGT-3’ 5’-TGCGGCATCTTCAAACCTCCATGA-3’ 
CD36 5’-GAGAACTGTTATGGGGCTAT-3’ 5’-TTCAACTGGAGAGGCAAAGG-3’ 
MER 5’-CCGCCTGAGCCCGTCAACATT-3’ 5’-CTCCGTCAGGCTGGAACAGT-3’ 
CR3 5’-AAGGTGTCCACACTCCAGAAC-3’ 5’-GAGGAGCAGTTTGTTTCCAAG-3’ 
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2.7 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA is a laboratory assay that enables quantitative measurement of antibodies or 
antigens. First described in 1971 (140), the ELISA fast became and still remains 
indispensible across a number of different scientific disciplines. For the experiments 
performed here, antigens of interest were tested through the use of sandwich ELISA. By 
this method, reactants are absorbed onto a plastic plate, such that they are immobilised to 
the surface. The antigen is “sandwiched” between two monoclonal antibodies that bind 
specifically to two distinct sites on the antigen (150). The amount of antigen is measurable 
by comparison against a set of standards with pre-determined quantities of antigen. The 
sandwich ELISA is a sensitive test and has reduced risk of cross-reactivity because of the use 
of two separate epitopes, or antibodies. 
 
ELISAs undertaken were conducted in 96-well Maxisorp plates (NUNC, Denmark). Figure 
2-9 (below) illustrates the principle of the ELISA process occurring in a single well, and 
corresponds to the outlined methods. 
 
This ELISA was devised from the manuscript published by Wu et al (109). The authors used 
a kit for detecting MER in cell lysates, instead to measure MER in human plasma (i.e. 
sMER). The antibodies and standards from the human total MER ELISA kit DYC-891 (R&D 
Systems, USA) were used by the same methods used for all ELISAs conducted. The kit and 
methods were first validated and optimised by spike and recovery and linearity of dilution, 
and fresh plasma samples were then tested accordingly. The reagents used are listed 
throughout the protocol, and represent the only deviations from the ELISA kit 
manufacturer’s instructions. 
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The capture antibody was reconstituted to a working concentration of 8 μg/mL in 
phosphate buffered saline (PBS) [SIGMA-ALDRICH, UK], and added to the wells. Capture 
antibody has a specific binding site for the antigen of interest. The plate was covered and 
incubated overnight at room temperature. The plate was then washed three times to 
remove any excess. This was performed with wash buffer (PBS + 0.05% Tween 20 [SIGMA-
ALDRICH, UK]). 
 
Reagent diluent (PBS + 1% bovine serum albumin [SIGMA-ALDRICH, UK]) was used as a 
block buffer (containing an excess of unrelated protein), and added to the wells to prevent 
the binding of any remaining well sites not occupied by capture antibody. The plate was 
incubated at room temperature for 1-2 hours. The plate was washed three times to remove 
any excess. 
 
Samples containing the antigen of interest were diluted (as appropriate) and added to wells 
(in duplicate) to bind to the capture antibody. The plate was covered and incubated at 
room temperature for 2 hours. The plate was then washed three times to remove any 
excess. 
 
The detection antibody was reconstituted to a working concentration of 200 ng/mL in 
reagent diluent, and was added to the wells. Biotinylated monoclonal detection antibody 
recognises and binds to a different site of the antigen of interest. Biotin is a low-molecular 
weight vitamin B which may, in turn, be bound. The plate was covered and incubated at 
room temperature for a further 2 hours. The plate was then washed three times to remove 
any excess. 
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Streptavidin conjugated with an enzyme, horseradish peroxidase (Streptavidin-HRP), was 
diluted to a working concentration of 1 in 200 in reagent diluent, and added to the wells. 
Strepatividin-HRP is a bacterial protein that has a high affinity to bind biotin (141). The 
plate was covered and incubated for 20 minutes outside of direct light. The plate was then 
washed three times to remove any excess. 
 
Substrate (1:1 mixture of H2O2 and Tetramethylbenzidine (R&D Systems) for the enzyme 
was added to the wells. The substrate is hydrolysed, producing a colour change (to blue) 
that is proportional to the amount of antigen that was present. The plate was covered and 
incubated for up to 20 minutes outside of direct light. 
 
This reaction is stopped using sulphuric acid, which causes a colour change (to yellow), and 
this colour change is spectrophotometrically analysed using a microplate reader ELX800 
(BIotek, USA) and the proprietary software KCJunior. These results were then displayed in 
Microsoft Excel 2010 and subsequently analysed with IBM SPSS v19 and/or Graphpad Prism 
v5. 
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Figure 2-9 ELISA principle (142) 
 
The steps are: capture antibody, then block buffer, then samples/standards, then detection antibody, then 
streptavidin-HRP, with washes between steps. Wells are coated with capture antibody, then block buffer added 
to occupy any free binding sites. Samples and standards are added to wells, with any antigen of interest 
intended to bind to capture antibody. Detection antibody is added, sandwiching the antigen. The addition of 
strepatividin-HRP binds to the biotin of the detection antibody. Substrate solution manifests a colour change 
proportional to the quantity of antigen of interest, and this reaction is halted using stop solution. The colour 
change is then measured by spectrophotometer. 
  
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
Paulie S, Perlmann H, Perlmann P. Enzyme-linked Immunosorbent 
Assay.  eLS: John Wiley & Sons, Ltd; 2001. 
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2.7.1 Data Interpretation 
In order to measure the amount of antigen of interest present, samples are tested 
alongside a set of standards which contain known-amounts of antigen. The measured 
colour is compared back to the known amount for all standards, and the resulting standard 
curve is used to ascertain the quantity of antigen present in samples. The r2 of the curve 
indicates the consistency of each duplicate and of the standards. An r2 of 1 indicates that all 
points lie on the curve, and an r2 of greater than or equal to 0.9 was considered acceptable. 
By plotting a standard curve and ascertaining the equation of the curve, the values 
returned by the spectrophorometer can be converted into concentrations of antigen found 
in each unknown sample. The standard curve can also be used to validate the ELISA, as the 
difference between standards should follow a predictable, consistent pattern. 
 
2.7.2 Spike and Recovery and Linearity of Dilution 
Spike and recovery and linearity of dilution are methods of validating the accuracy of ELISA 
experiments. Serial dilutions of samples are performed and samples are either left un-
spiked, or spiked with a known quantity of the antigen of interest. The aim of assay 
development is to maximise the signal-to-noise ratio whilst achieving identical results for 
spike alone compared with spiked samples. By performing these tests, it confirms that both 
the ELISA kit works correctly and excludes the possibility of interference from another 
antigen found in the samples. The linearity of dilution indicates whether there is a 
substance present in the samples that is interfering, as in this case it is expected that the 
interference identified will decrease with increasing dilution. 
 
  
62 
 
2.8 Flow Cytometry 
2.8.1 The Principles of Flow Cytometry 
Flow cytometry is the measurement of the characteristics of cells or particles in a fluid 
stream as they pass through a light source (143). Sample taken up by the flow cytometer 
must firstly be ordered into a stream of single particles through the fluidics system. This 
system consists of a central core, through which the sample is passed, and a surrounding 
sheath containing sheath fluid (see Figure 2-10). The sheath fluid flows faster than sample 
and this pressure differential causes a drag effect on the narrowing central core resulting in 
a parabolic flow; focusing the cells or particles into a single stream through this process of 
hydrodynamic focusing (143).  
 
 
Figure 2-10 The principles of hydrodynamic focusing 
 
The sample is channelled down the central core; the faster flow of the surrounding sheath fluid creates a drag 
effect, focusing the cells into a single stream (144). 
 
At the interrogation point, a beam of monochromatic light is projected upon the cells or 
particles (145), and collection optics direct the light scatter or fluorescent light of the cells 
or particles to an electronic network (143). This means that particular wavelength bands 
are isolated (145). The light signals from each cell or particle is detected by the electronic 
network which converts these signals to a measure proportional to light intensity. These 
measurements are recorded by computer to be analysed and interpreted by the user. 
 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
Rahman M. Introduction to Flow Cytometry. AbD Serotec; 2006 [cited 
2006 8 August]; Available from: 
http://static.abdserotec.com/uploads/Flow-Cytometry.pdf. 
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Emitted light is measured by fluorescence channels or detectors which are specific for 
different wavelengths. This is in turn determined by optical filters that may either block or 
transmit certain wavelengths. The photomultiplier tubes are detectors termed FL- followed 
by a number to indicate the range of wavelength each may detect (143). The filter FL-4 is 
used to detect far red fluorescence. 
 
2.8.2 The Principles of pHrodo 
Phagocytosis assays have been undertaken with a variety of methods, and a number have 
been undertaken investigating phagocytosis in adult-onset SLE. However, a number of 
potential phagocytosis assay protocols could result in a overestimation of phagocytosis 
with assumed internalisation when a bacterium or cell has instead remained bound to the 
cell surface (146). The methods described by Miksa et al (146) outline a staining method by 
which internalisation can be assured. pHrodo (Invitrogen, USA) is a fluorescent dye which 
emits red light in response to and with increasing intensity in relation to decreasing pH. As 
described in section 1.3, after internalisation a phagocytosed particle fuses with the 
lysosome. The lysosome is an acidic sac (45) and the fusion of the phagosome and 
lysosome therefore exposes the phagocytosed particle to an acidic environment (146). The 
fluorescence emission can be observed visually (see Figure 2-11) and can be detected and 
measured by flow cytometry. E. coli particles can be obtained pre-stained with pHrodo, and 
it is also possible to stain cells independently, used in the aforementioned study to 
measure apoptotic cell clearance (146).  
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Figure 2-11 Images illustrating pHrodo fluorescence in association with apoptotic cell attachment (146)  
 
The above graphics show: (a) there is minimal fluorescence compared with engulfment (b), where there is clear 
fluorescence. This occurs due to fusion of the phagosome (internalised cell stained with pHrodo) with the cell 
lysosome, resulting in a drop in pH and resulting in red fluorescence. 
 
 
2.8.3 Protocol (Monocytes + pHrodo E. coli) 
Following on from the monocyte separation protocol (section 2.3), CD14+ cells were re-
suspended in RPMI, to a working concentration of 1 x 105 cells per 100 µl. 1 x 105 cells were 
added to each flow cytometry tube, and were then washed with uptake buffer (HBSS 
[Invitrogen, USA] and HEPES 20mM [SIGMA-ALDRICH, UK] at pH 7.4) and centrifuged at 670 
xg for 5 minutes. The supernatant was removed, and a total of 50 µl of solution was mixed 
with the CD14+ cells (consisting of pHrodo E. coli BioParticles conjugates [Invitrogen, USA] 
or uptake buffer plus 10% fresh serum, fresh plasma plasma or neither [in which case 
uptake buffer was used in substitution]). These samples were then immediately kept on ice 
or incubated at 37oC with 5% CO2 for a pre-determined time course. At this point, samples 
were washed with uptake buffer and centrifuged at 670 xg for 5 minutes. The supernatant 
was removed and the cells were resuspended in uptake buffer. The samples were then 
tested by Flow Cytometer (Cytomics FC 500 MPL [BECKMAN COULTER, UK]). As pHrodo 
positivity is marked by red light emission, FL-4 was used in detection. The data was 
recorded by computer using MXP software (BECKMAN COULTER, UK). Analysis of flow 
cytometry data was performed using FlowJo v7.6.5 (Tree Star, USA). 
 
 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
 
Miksa M, Komura H, Wu R, Shah KG, Wang P. A novel method to 
determine the engulfment of apoptotic cells by macrophages using 
pHrodo succinimidyl ester. Journal of immunological methods. 
2009;342(1-2):71-7. 
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2.8.4 Data Interpretation and Analysis 
Flow Cytometry assesses the characteristics of cells or particles are assessed in a number of 
ways. In order to analyse a cell population, this population must first be “gated” from any 
debris or dead cells, for example. A density plot graphs particles according to size, by 
forward scatter, and cell granularity, by side scatter, and groups can then be gated to 
return a purer population of cells (see Figure 2-12). 
 
 
Figure 2-12 Flow cytometry of a population of separated CD14+ cells 
 
The above flow cytometry scatter plots show: (a) post-cell separation CD14
+ 
population; (b) gated monocyte 
population. 
 
The gated cells are then plotted in a histogram, with the x-axis for fluorescence or light 
scatter intensity, and the cell count on the y-axis. This will be expected to produce one or 
more normally-distributed peaks. As pHrodo fluoresces red, and is therefore detected with 
FL4, pHrodo flow cytometry histograms have been plotted according to FL4 fluorescence. A 
negative control of monocytes alone was used to determine a relative baseline from which 
to measure phagocytosis (see Figure 2-13). Further controls were used of samples stored 
on ice to provide another baseline for comparison with cells incubated at 37oC. Cells stored 
on ice act as negative controls; so amount of phagocytosis occurring would be limited in 
a b 
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comparison to incubated cells. By deducting determined pHrodo positivity of ice-stored 
samples from incubator-stored samples, an assessment of the amount of phagocytosis was 
made. 
 
 
 
Figure 2-13 Example histograms illustrating pHrodo positivity 
 
The above are examples of histograms comparing the number of cells with pHrodo positivity (FL-4 x-axis, cell 
count y-axis). Three test conditions are shown: (a) monocytes alone; (b) monocytes in 10% serum on ice; (c) 
monocytes in 10% serum, incubated. 
  
a b c 
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2.9 Monocyte Stimulation 
An experiment was designed to attempt to ascertain the conditions or environments that 
may result in the cleavage of MER from the surface of the phagocyte. Adult HC monocytes 
were exposed to a number of environments associated with SLE/JSLE for a pre-determined 
length of time. Also of interest was the effect that these same environments may have on 
the expression of the phagocytic markers of interest: CD36, MER and CR3. 
 
CD14+ cells were separated from PBMCs from adult HC whole blood according to protocols 
outlined previously (sections 2.2, 2.3). 2 x 105 cells in RPMI media were placed into 
separate wells on a 96-well plate and incubated at 37oC for 2 hours to enable them to 
adhere to the plate. At this time point, media was removed and replaced with RPMI media 
containing different stimulators. RPMI media was reapplied for negative controls. LPS was 
added to RPMI media at a concentration of 50 ng/mL. IFNα was added to RPMI media at 
concentrations including 100 pg/mL, 500 pg/mL, 1000 pg/mL and 2000 pg/mL. TNFα was 
added to RPMI media at concentrations including 100 pg/mL, 500 pg/mL and 1000 pg/mL. 
Monocytes were also exposed to apoptotic neutrophils, at a ratio of 1:1 (apoptotic 
neutrophils : monocytes), 2:1 and 4:1. The methods for inducing neutrophil apoptosis are 
outlined below, in section 2.9.1. The monocytes were incubated at 37OC, for either 2 or 6 
hours. The supernatant was extracted and stored at -70OC. Any supernatant with 
neutrophils was first centrifuged at 670 xg for 3 minutes to pellet the neutrophils. RNA 
extraction was performed on the adherent cells according to protocol, outlined in section 
2.4. 
 
Extracted supernatants were measured for presence of sMER by ELISA the assay protocol 
described previously (section 2.7). 
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Reverse transcription of RNA was performed (section 2.6.1), and resulting cDNA was tested 
by real-time qPCR by previously outlined protocols (section 2.6.2) for gene expression 
levels of β2M, CD36, MER and CR3. 
 
2.9.1 Inducing Neutrophil Apoptosis 
Neutrophils were separated according to the previously outlined protocols (section 2.2). 
Neutrophils were resuspended in RPMI-1640 at 1 x 106 cells and apoptosis was induced by 
adding 10 μg/mL of cyclohexamide, before incubating the cells at 37oC for 2 hours. An 
aliquot of neutrophils was left unexposed to cyclohexamide so that stimulated and 
unstimulated neutrophils could be stained with propidium Iodide (PI) and annexin V, to 
measure the amount of necrosis or apoptosis undergone. This was performed and analysed 
by flow cytometry. First, the cell profiles were examined for forward and side scatter to 
confirm the purity of the cell population (Figure 2-14). 
 
Figure 2-14 Flow cytometry graphs of a population of neutrophils 
 
The above scatter plots are obtained from flow cytometry of a population of neutrophils, presenting forward 
scatter (x-axis) against side scatter (y-axis). (a) shows the neutrophil population forward and side scatter 
profiles, whilst (b) shows a gated neutrophil population. 
 
 
PI staining is measured by FL-3 and indicates the number of necrotic cells present, whilst 
annexin V is measured by FL-1 and gives indication as to the number of apoptotic cells. 
b a 
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Figure 2-15 is an example of cells stained with both; and the proportion of apoptotic cells is 
indicated by the Q3 area which encompasses cells which stained positive for annexin V and 
negative for PI. To ascertain the percentage of apoptotic cells present, the percentage of 
annexin V-positive neutrophils at the 0 hour time-point (control) was deducted from the 
percentage of annexin V-positive neutrophils at the 2 hour time-point, giving a net level of 
apoptosis. So, in Figure 2-15 for example, net apoptosis would be calculated as 62.8% of 
cells.  
 
 
 
Figure 2-15 Flow Cytometry assessing cells for the percentage of apoptosis in a neutrophil population 
 
The above scatter plots show the annexin V positivity (FL-1, x-axis) and PI positivity (FL-3, y-axis) in a population 
of neutrophils induced for apoptosis with cyclohexamide (10 μg/mL): (a) shows the measured fluorescence at 
the 0 hour time-point (i.e. non-induced); and (b) the 2 hour time-point (apoptosis-induced). 
 
  
a 
b 
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2.10 Statistical Analyses 
 
Statistical analyses were performed using IBM SPSS v19.0.0, and all graphical displays 
produced using either Microsoft Excel 2010 or GraphPad Prism v5. All datasets were 
assessed for the distribution of data; all were non-parametric. The non-parametric data 
have thus been displayed in text and graphically as (median [interquartile range]). A 2-
tailed Mann-Whitney U test was utilised for analysing statistical significance between 
groups, with p < 0.05 taken to indicate statistical significance. Correlations were evaluated 
using the Spearman’s rank correlation test. 
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3 Results 
3.1 Real-time qPCR of monocytes and macrophages 
3.1.1 Validation and Optimisation 
First, methods were validated and the experiments optimised using adult HC monocyte and 
macrophage cDNA. They were considered validated and optimised providing triplicate 
results showed consistency, the standard curve demonstrated good (80 – 120%) efficiency, 
and the dissociation curve showed a single peak of fluorescence. β2M was selected as the 
reference gene after comparison with GAPDH: both appeared to be stably expressed, but 
GAPDH expression has been reported as variable within cell populations (138) and 
depending on experimental settings (137). Standard and dissociation curves from initial 
validation and optimisation experiments are shown in Figure 3-1a, b, c and d. 
 
 
 
a 
b 
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Figure 3-1 Example standard curves and dissociation (melting) curves from initial validation experiments 
measuring β2M expression (a & b) and CD36 expression (c & d) 
 
The data gathered from these initial experiments are shown in Table 3-1.  
 
Table 3-1 Data from initial qPCR of mRNA from adult healthy control macrophages (Mφ) and THP-1 cell line 
monocytes 
 
The primers were then utilised in a series of experiments testing the gene expression of a 
number of receptors associated with apoptotic cell clearance in monocytes and 
macrophages from JSLE and control donors. 
B2M MERKT Relative CD36 Relative CR3 Relative
Quantity Quantity Expression Quantity Expression Quantity Expression
(copies) (copies) Ratio (copies) Ratio (copies) Ratio
Mφ 1 1311 970.4 0.74 422.1 0.32 1738 1.33
Mφ 2 1444 2898 2.01 582.7 0.40 1424 0.99
Mφ 3 1538 1225 0.80 1606 1.04 1592 1.04
THP-1 Mo 346 17.29 0.05 88.72 0.26 255 0.74
Mφ 5 992 923.1 0.93 2046 2.06 3675 3.71
Mφ 6 677 1284 1.90 4979 7.36 4162 6.15
c 
d 
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3.1.2 mRNA expression of phagocytic markers on JSLE and control monocytes 
Real-time qPCR was performed to analyse the gene expression of a number of receptors. 
These were CD36, MER and CR3 and they were selected on the basis of their associations 
with the process of apoptotic cell clearance (section 0). Given the hypothesised relationship 
between failing apoptotic cell clearance and SLE pathogenesis, the gene expression of 
these receptors was investigated to attempt to identify and analyse differences between 
the monocytes of a HC and a JSLE patient (see  
Objectives). Figure 3-2 presents the data of the mRNA expression of these receptors in 
monocytes from JSLE patients and controls. 
 
CD14+ cells from paediatric HC and JSLE patients were separated from PBMCs. RNA 
extraction and reverse transcription of these CD14+ cells was performed and resulting 
cDNA was tested for expression of three receptors associated with apoptotic cell clearance 
(CD36, CR3, MER), compared against that of a reference gene (β2M) for relative expression 
ratios. JSLE monocyte expression (n=6) was compared against HC monocyte expression 
(n=6). 
 
CD36 expression was found to be significantly higher in JSLE monocytes (0.96 [0.68-1.34]) 
compared with HC monocytes (0.53 [0.39-0.70]; p=0.025) (Figure 3-2a). There was no 
difference in expression of MER in JSLE monocytes (0.47 [0.30-0.74]) compared with HC 
monocytes (0.30 [0.19-0.44]; p=0.200) (Figure 3-2b). In CR3 expression too, no difference 
was found in JSLE monocytes (0.65 [0.49-0.96]) compared with HC monocytes (0.77 [0.71-
1.32]; p=0.150) (Figure 3-2c). 
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Figure 3-2 mRNA expression of phagocytic markers on JSLE and control monocytes 
 
Real-time qPCR was performed with primers for β2M (reference gene) and: (a) CD36; (b) MER; (c) CR3. These 
were tested in HC (n=6) and JSLE (n=6) monocytes. Data are shown as median (interquartile range), and p-
values were determined by the Mann-Whitney U test.  
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3.1.3 mRNA expression of phagocytic markers on JSLE and control 
macrophages 
 
Monocyte derived-macrophages were also analysed using the same primers to investigate 
gene expression. As a much more capable phagocyte than the monocyte, this would 
demonstrate whether expression trends were consistent in monocytes and macrophages 
or whether there were discrepancies. Figure 3-3 shows the data measured from 
macrophage mRNA of HC and JSLE patients.JSLE macrophages expression (n=3) was 
compared against HC macrophages expression (n=9). 
 
There was no difference in expression of CD36 by JSLE macrophages (1.02 [0.64-2.18]) 
compared with HC (0.58 [0.48-0.99]; p=0.166) (see Figure 3-3a). There was also no 
difference in expression of MER by JSLE macrophages (0.85 [0.74-0.86]) compared with HC 
macrophages (1.14 [0.78-1.73]; p=0.166) (see Figure 3-3b),  and the same was true of CR3 
expression, with statistically no difference in JSLE (0.49 [0.26-0.62]) compared with those of 
HC (1.40 [0.35-2.23]; p=0.229) (see Figure 3-3c). 
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Figure 3-3 mRNA expression of phagocytic markers on JSLE and control macrophages 
 
Real-time qPCR was performed with primers for β2M (reference gene) and: (a) CD36; (b) MER; (c) CR3. These 
were tested in HC (n=9) and JSLE (n=3) macrophages. Data are shown as median (interquartile range), and p-
values were determined by the Mann-Whitney U test. 
  
77 
 
3.2 Soluble MER (sMER) ELISA 
This section shows results of work to measure the amount of sMER in plasma samples of 
JSLE patients, compared with inflammatory (JIA) and non-inflammatory (HC) controls (see  
Objectives). 
 
3.2.1 Spike and Recovery and Linearity of Dilution 
Conducting a spike and recovery ELISA ensures that the ELISA kit functions correctly, and 
can be used to identify matrix interference, as the sample may contain components that 
affect the assay. Research conducted at our laboratory has shown evidence of matrix 
interference affecting a number of cytokine assays, including TNFα, IL-17, IL-21 and IL-23 
(147). As such, it was important to verify the integrity of the ELISA before testing patient 
samples. 
 
The study investigating sMER presence in adult-onset SLE (109) used plasma samples 
diluted to a concentration of  1 in 10, so for this experiment  dilutions of 1 in 5, 1 in 10, 1 in 
20, and 1 in 40 were used to validate the ELISA kit and methods. This was aiming to confirm 
that adequate recovery of MER was possible irrespective of the dilution use. The standard 
curve (Figure 3-4) shows good reliability, with an R2 of 0.9993. 
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Figure 3-4 sMER Spike and Recovery ELISA Standard Curve 
 
The graph, plotting concentration against absorbance, gives the formula used to calculate 
amounts of sMER present (in ng/mL), and the R2 was 0.9993 so the results can be 
considered reliable. 
 
From this, measured concentrations were ascertained and the amount present in un-spiked 
samples deducted from the spiked, and recovery calculated by dividing by the expected 
amount. The results of the spike and recovery experiment are summarised in Figure 3-5. 
 
y = -0.0069x2 + 0.278x + 0.018 
R² = 0.9993 
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Figure 3-5 sMER Spike and Recovery ELISA results 
 
Recovery percentages are shown (y-axis), with increasing dilutions across the x-axis of 1 in 5, 1 in 10, 1 in 20, 
and 1 in 40. Three JSLE plasma samples were tested (L3e, L35g, L40d) and one HC (C35a) to confirm absence of 
matrix interference. 
 
Each coloured bar denotes a different patient and sample: JSLE (L) and control (C), followed 
by the unique numerical coding used, followed by a lower case letter indicating the clinic 
visit. Recovery was consistent across all dilutions, but a 1 in 5 dilution was opted for as 
increasing dilutions decrease the potential accuracy of the results. 
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3.2.2 sMER ELISA 
An ELISA for the measurement of sMER concentrations was undertaken with 1 in 5 
dilutions of plasma samples, to compare JSLE against inflammatory controls, Juvenile 
Idiopathic Arthritis (JIA) and HC. 
 
3.2.2.1 Demographics 
Patient samples were age and sex-matched with HC. Table 3-2 shows the demographic 
data, and the disease and therapeutic profiles of the patient cohort. 
 
 JSLE JIA HC 
Frequency 15 10 15 
Median age [years (range)] 15 (3-18) 10.5 (8-17) 14 (2-17) 
Gender, F:M (%) 9:6 (60:40) 8:2 (80:20) 9:6 (60:40) 
Active Disease (%) 5 (33) 4 (40)  
Median BILAG Score (range) 2 (0-15)   
Corticosteroids 
Number of patients (%) 
Median dose, mg/day (range) 
 
10 (66) 
10 (1-25) 
 
3 (30) 
Unknown 
 
Antimalarials 
DMARD 
Biologics 
Others 
13 (87) 
11 (73) 
2 (13) 
3 (20) 
0 (0) 
5 (50) 
8 (80) 
3 (30) 
 
Median ESR (range) 7 (1-50) 3.5 (0-72)  
Median CRP (range) 4 (<4-37.3)   
C3 (range) 1.05 (0.75-
1.98) 
  
C4 (range) 0.16 (0.09-
0.42) 
  
Table 3-2 sMER ELISA Demographic Data 
 
This table presents the demographics, disease and therapeutic profiles, and clinical biomarker results of the 
JSLE, JIA and HC groups (wherever possible). Any JSLE patients with a BILAG score of A or B for any organ 
system, and any JIA patients with limited movement in one or more joints at the time of sample collection were 
considered to have active disease. Patients taking the listed medications at the time of sample collection were 
included in these groups. Antimalarials –Hydroxychloroquine; DMARD (disease-modifying anti-rheumatic drug) 
– Mycophenolate Mofetil, Azathioprine, Methotrexate; Biologics – JSLE – Rituximab or Infliximab, JIA – 
unspecified; Others – JSLE – Cyclophosphamide, IVIG, JIA - Aspirin  
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3.2.2.2 Increased concentration of sMER in JSLE compared to JIA and HC 
The results of this ELISA are shown in Figure 3-6. The concentrations of sMER were 
significantly greater in JSLE patients (median 15.2ng/mL, [interquartile range 11.1-21.2]) 
compared with HC (6.2, [5.8-8.6]; p<0.001). Comparing JSLE with JIA patients, the greater 
concentrations observed in JSLE patients were statistically significant (10.4, [8.2-11.7]; 
p=0.014). sMER concentrations were also found to be significantly greater in JIA patients 
compared with HC (p=0.001). 
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Figure 3-6 sMER ELISA Results – Vertical Scatter Graph 
 
This graph displays the measured concentrations of sMER (ng/mL) of samples in each group, JSLE (n=15), JIA 
(n=10) and HC (n=15). Data are shown as median (interquartile range), and p-values were determined by the 
Mann-Whitney U test. 
 
Next, correlation relationships were investigated within the test groups. The scatter plots 
(Figure 3-7) show the distribution of sMER concentrations against age across the three 
groups. There is strong inverse correlation between correlation and age in JSLE patients (r=-
0.714, p=0.003) (Figure 3-7a). This is not a pattern that is replicated in JIA (r=0.345, 
p=0.328) (Figure 3-7b) or HC (r=0.048, p=0.864) (Figure 3-7c). 
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Figure 3-7 sMER-age scatter plots 
 
The scatter plots above chart JSLE (a), JIA (b) and HC (c) sMER concentrations (ng/mL) against patient age. 
Correlation data (Spearman’s rank correlation test) is shown for each group. 
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Figure 3-8 scatter plots show disease activity and levels of commonly used clinical 
biomarker of JSLE in the against sMER concentration in the JSLE group. The BILAG disease 
activity scores suggest a positive correlation with sMER concentration (r=0.472), but this 
was not statistically significant (p=0.075) (Figure 3-8a).  There was no evidence of 
correlation between ESR and sMER (r=-0.375; p=0.168) (Figure 3-8b), nor between CRP and 
sMER (r=-0.016, p=0.954) (Figure 3-8c). There was also no evidence of correlation between 
complement levels and sMER concentration; C3 (r=0.132, p=0.639) (Figure 3-8d), and C4 
(r=0.113, p=0.688) (Figure 3-8e). 
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Figure 3-8 Scatter plots of BILAG, ESR, CRP, C3 and C4 against sMER concentration 
 
The scatter plots chart the sMER concentrations of JSLE patients against the BILAG disease activity index (a) and 
a number of biomarkers: ESR (b), CRP (c), C3 (d) and C4 (e). The correlation data (Spearman’s rank correlation 
test) is shown on each graph. 
 
The JSLE group was divided by gender to investigate for any differences between males and 
females in sMER concentration (Figure 3-9). In the tested samples, male JSLE patients had 
greater concentrations of sMER (22.39 [16.28-34.08]) than female patients (12.15 [10.39-
85 
 
16.50]; p=0.036). This is also reflected by the generally-higher disease activity BILAG scores 
found in males: (median 3.5, range 1-15), compared with females: (1, 0-6), albeit not a 
significant difference (p=0.187, Mann-Whitney U test). 
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Figure 3-9 Vertical scatter of sMER concentrations in males and females with JSLE 
 
The above graph separates JSLE patients into males (n=6) and females (n=9) to show sMER concentrations 
(ng/mL) in each. Data are shown as median (interquartile range), and p-values were determined by the Mann-
Whitney U test. 
 
The JSLE patients were split according to their therapeutic profiles at the time of sample 
collection (see Table 3-2). Figure 3-10 separates patients according to whether or not they 
were receiving hydroxychloroquine, and Figure 3-11 separates patients according to 
whether or not they were receiving corticosteroids. 
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Figure 3-10 sMER concentrations of JSLE patients divided according to current hydroxychloroquine therapy 
 
The vertical scatter separates JSLE patients according to whether or not they were treated with 
hydroxychloroquine at the time of sample collection: not currently taking hydroxychloroquine therapy (No HCQ, 
n=3), patients taking hydroxychloroquine therapy (HCQ, n=12). Data are shown as median (interquartile range), 
and p-values were determined by the Mann-Whitney U test. 
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Comparing the sMER profile of patients on medications, those taking hydroxychloroquine 
(12.50 [10.93-18.56]) have significantly higher levels of sMER than those not taking 
hydroxychloroquine (33.00 [24.44-37.31]; p=0.012). 
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Figure 3-11 sMER concentrations of JSLE patients divided according to current corticosteroid (CS) therapy 
 
The vertical scatter separates JSLE patients according to whether or not they were treated with corticosteroids 
at the time of sample collection: not currently taking corticosteroids (No CS; n=5) compared with those taking 
corticosteroids (CS; n=10). Data are shown as median (interquartile range), and p-values were determined by 
the Mann-Whitney U test. 
 
There was no difference between the sMER concentrations of those on corticosteroid 
treatment (17.16 [12.56-23.25]) and those not on corticosteroid treatment (16.98 [12.86-
28.39]; p=0.953).  
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3.3 Monocyte Phagocytosis of pHrodo E. coli 
This series of experiments was intended to measure phagocytosis by adult healthy control 
monocytes, comparing function in plasma from JSLE and HC patients (see  
Objectives). 
 
3.3.1 Validation and Optimisation 
To validate and optimise methods, a number of assays were undertaken. Three time-points 
were used (30, 60, and 90 minutes), to ascertain the levels of phagocytosis at each in order 
to determine which time-point would be most appropriate, to allow sufficient phagocytosis 
to take place but not so long as to introduce other limiting factors for phagocytosis. 
Monocytes were incubated in the absence of pHrodo to establish a baseline at which 
pHrodo positivity should be around 0%, due to a lack of phagocytosis. Monocytes and 
pHrodo E. coli were either stored on ice or incubated at 37oC. Monocytes stored on ice 
were used as negative controls in which there should be very little evidence of 
phagocytosis occurring. The percentage of pHrodo positive monocytes on ice was therefore 
deducted from the percentage of pHrodo positive monocytes incubated at 37oC to give a 
corrected level of phagocytosis. Monocytes and pHrodo E. coli were also tested, with and 
without serum, to assess for any differences. It was expected that phagocytosis in serum 
would be greater than without, since serum contains opsonising agents such as 
complement. The histograms resulting from one set of conducted assays are shown in 
Figure 3-12, Figure 3-13 and Figure 3-14. 
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3.3.1.1 30 minutes 
 
Figure 3-12 Flow Cytometry histograms of adult control monocytes incubated with pHrodo-stained E. coli for 
30 minutes 
 
These histograms show levels of pHrodo positivity detected by flow cytometry, after monocytes were incubated 
at set conditions for 30 minutes. (a) monocytes in the absence of serum or pHrodo E. coli; (b) monocytes 
incubated on ice with pHrodo E. coli without serum; (c) monocytes incubated on ice with pHrodo E. coli with 
10% AB serum; (d) monocytes incubated at 37oC with pHrodo E. coli without serum; (e) monocytes incubated at 
37
o
C with pHrodo E. coli with 10% AB serum.  
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3.3.1.2 60 minutes 
 
Figure 3-13 Flow Cytometry histograms of adult control monocytes incubated with pHrodo-stained E. coli for 
60 minutes 
 
These histograms show levels of pHrodo positivity detected by flow cytometry, after monocytes were incubated 
at set conditions for 60 minutes. (a) monocytes in the absence of serum or pHrodo E. coli; (b) monocytes 
incubated on ice with pHrodo E. coli without serum; (c) monocytes incubated on ice with pHrodo E. coli with 
10% AB serum; (d) monocytes incubated at 37oC with pHrodo E. coli without serum; (e) monocytes incubated at 
37oC with pHrodo E. coli with 10% AB serum.  
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3.3.1.3 90 Minutes 
 
Figure 3-14 Flow Cytometry histograms of adult control monocytes incubated with pHrodo-stained E. coli for 
90 minutes 
 
These histograms show levels of pHrodo positivity detected by flow cytometry, after monocytes were incubated 
at set conditions for 90 minutes. (a) monocytes in the absence of serum or pHrodo E. coli; (b) monocytes 
incubated on ice with pHrodo E. coli without serum; (c) monocytes incubated on ice with pHrodo E. coli with 
10% AB serum; (d) monocytes incubated at 37oC with pHrodo E. coli without serum; (e) monocytes incubated at 
37oC with pHrodo E. coli with 10% AB serum. 
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The data from these histograms (Figure 3-12, Figure 3-13 and Figure 3-14) have been 
tabulated, and the differences calculated (Table 3-3). The results indicate that 30 minutes is 
a sufficient time-point to allow for phagocytosis of E. coli to occur. There is a slightly 
increased proportion of phagocytosis occurring at 60 minutes compared with 30 minutes, 
but there is no discernable increase between 60 minutes and 90 minutes. Certainly there is 
no increase in phagocytosis at 90 minutes compared with 60 minutes. The increase 
between 30 and 60 minutes is also quite small, suggesting that the majority of unrestricted 
phagocytosis occurs within the first 30 minutes in these experimental conditions. For these 
reasons, 30 minutes was selected as the time-point for experiments investigating monocyte 
phagocytosis of pHrodo E. coli. 
a 
No Serum 
    
b 
10% AB Serum 
  
           % Phagocytosis 
 
  % Phagocytosis 
  Ice Incubated Difference 
 
  Ice Incubated Difference 
30 mins 1.5 42.1 40.6 
 
30 mins 1.7 63.1 61.4 
60 mins 1.7 44.1 42.4 
 
60 mins 2.9 69.8 66.9 
90 mins 0.9 51.4 50.5 
 
90 mins 1.0 67.5 66.5 
Table 3-3 Method validation and optimisation - percentage of phagocytosis across three time points 
 
Tables presenting phagocytosis data with samples (n=3) placed on ice, incubated, and the difference between 
the two in no serum (a) and 10% AB serum (b) environments. 
 
The importance of environment was also tested in these preliminary experiments. The 
results in Table 3-4 indicate that an environment of serum was more conducive to the 
occurrence of phagocytosis than in its absence.  
  No serum 10% AB serum 
30 mins 40.6 61.4 
60 mins 42.4 66.9 
90 mins 50.5 66.5 
Table 3-4 Phagocytosis in a no serum environment compared with 10% AB serum  
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3.3.2 Monocyte phagocytosis of pHrodo E. coli in JSLE and HC serum and plasma 
Figure 3-15 presents the results of comparing the performance of phagocytosis by adult HC 
monocytes in serum versus plasma. The four different sample conditions were tested in a 
repeated number of experiments (n=5). Phagocytosis of pHrodo E. coli in adult HC 
monocytes in HC serum (39.00 [29.20-52.40]) was comparable with those in HC plasma 
(43.30 [36.85-47.40]), with no significant difference (p=0.841). In JSLE environments, again, 
the results found showed similar phagocytic performance serum (23.20 [19.00-37.95]), as 
in plasma (27.10 [16.55-38.15]), with no statistically significant difference (p=1.000). 
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Figure 3-15 Monocyte phagocytosis of pHrodo E. coli, comparing performance in serum versus plasma 
 
The vertical scatters above compare the % of monocytes that have phagcytosed pHrodo-stained E. coli within 
the 30 minute incubation period, in the HC group (n=5) and the JSLE group (n=5). Data are shown as median 
(interquartile range), and p-values were determined by the Mann-Whitney U test. 
 
With the absence of a discernable difference between an environment of serum or plasma, 
experiments were thereafter continued in plasma. We compared the performance of adult 
HC monocytes in HC plasma (n=6) with JSLE plasma (n=5). Figure 3-16 is a vertical scatter 
illustrating the results found which suggest occurrence trend towards increased 
phagocytosis in HC plasma (44.95 [32.73-48.88]) compared with JSLE plasma (32.60 [22.85-
38.15]). However, this difference did not reach statistical significance (p=0.126). 
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Figure 3-16 Monocyte phagocytosis of pHrodo E. coli comparing performance in plasma from HC with plasma 
from JSLE patients 
 
The vertical scatters show the % monocytes that phagocytosed pHrodo-stained E. coli within the 30 minute 
incubation period, if exposed to HC (n=6) or JSLE (n=5) plasma. Data are shown as median (interquartile range), 
and p-values were determined by the Mann-Whitney U test. 
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3.4 Monocyte Stimulation 
The results outlined here refer to experiments conducted to measure sMER concentration 
in supernatant, and to measure adult healthy control monocyte mRNA expression of CD36, 
MER and CR3 expression following exposure to LPS, IFNα, TNFα and apoptotic neutrophils 
(see  
Objectives).  
 
3.4.1 sMER ELISA 
This sMER ELISA was performed with supernatant diluted in reagent diluent, to a working 
concentration of 1 in 5, as the amount of sMER that might be present was unknown. The 
standard curve is presented in Figure 3-17, and results calculated from this are displayed in 
Table 3-5. 
 
Figure 3-17 Monocyte Stimulation sMER ELISA Standard Curve 
 
The standard curve graph charts the measured absorbance against the known concentrations of standard.  
 
The results in Table 3-5 show that there were no measurable levels of sMER present in the 
samples. 
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Concentration 
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  2 hour time-point 
supernatant 
sMER concentration (ng/mL) 
6 hour time-point 
supernatant 
sMER concentration (ng/mL) 
Monocytes alone 0.00 0.00 
LPS 50 ng/mL 0.00 0.00 
IFNα 100 pg/mL 0.00 0.00 
IFNα 500 pg/mL 0.00 0.00 
IFNα 1000 pg/mL 0.00 0.00 
IFNα 2000 pg/mL - 0.00 
TNFα 100 pg/mL - 0.00 
TNFα 500 pg/mL - 0.00 
TNFα 1000 pg/mL - 0.00 
Apoptotic neutrophils (AN) 1:1 0.00 0.00 
Apoptotic neutrophils (AN) 2:1 0.00 0.00 
Apoptotic neutrophils (AN) 4:1 0.00 0.00 
Table 3-5 sMER concentrations of supernatants following exposure of monocytes to test environments 
 
Two separate experiments were undertaken with two separate adult HC donors’ monocytes. The 
concentrations tested are presented in the table; apoptotic neutrophils (AN) ratios refer to the concentration of 
AN:monocytes. IFNα, interferon alpha; LPS, lipopolysaccharide; TNFα, tumour necrosis factor alpha. 
 
The apoptotic profiles of neutrophils were as follows: 
Net apoptosis at 2 hour time-point – 25% of neutrophils 
Net apoptosis at 6 hour time-point – 63% of neutrophils 
 
As a result, the experiment was repeated with supernatants diluted to a concentration of 1 
in 2: the highest concentration possible with the volume of supernatant available. Once 
again, sMER was not present at detectable levels. 
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3.4.2 mRNA expression of phagocytic markers on JSLE and control monocytes 
following exposure to different environments 
 
3.4.2.1 MER Expression 
 
The results following qPCR for MER expression are shown in Figure 3-18. In response to the 
environments tested, expression of MER appeared to remain mostly stable at the two time-
points. At the 2 hour time-point, the trend was for a down-regulation of expression 
observed in all except for monocytes exposed to IFNα at the concentration 1000 pg/mL. 
However, the down-regulation was generally small, except with LPS, IFNα (500 pg/mL) and 
apoptotic neutrophils (AN) 4:1. This down-regulation was again observed with LPS and AN 
4:1 at the 6 hour time-point, albeit with only a small level of down-regulation. TNFα 
exposure appeared to up-regulate MER expression by monocytes across the three tested 
concentrations. This suggests that the presence TNFα may increase the expression of the 
MER tyrosine kinase receptor and potentially increase the capacity for apoptotic cell 
clearance. Other factors appear to down-regulate MER expression and may, therefore, 
negatively impact upon apoptotic cell clearance. 
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Figure 3-18 mRNA expression of MER in adult control monocytes in response to different environments 
 
Bar charts present relative expression ratios and fold change data for the test conditions. (a) relative expression 
ratios of the gene expression of monocytes at the 2 hour time-point; (b) fold changes of the gene expression of 
monocytes at the 2 hour time-point; (c) relative expression ratios of the gene expression of monocytes at the 6 
hour time-point; (d) fold changes of the gene expression of monocytes at the 6 hour time-point. Apoptotic 
neutrophils (AN) ratios refer to the concentration of AN:monocytes. IFNα, interferon alpha; LPS, 
lipopolysaccharide; TNFα, tumour necrosis factor alpha. 
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3.4.2.2 CD36 Expression 
 
The results following qPCR for CD36 expression are shown in Figure 3-19. CD36 expression 
also appeared variable in the different test conditions. There was a negligible change in the 
majority of conditions, though some up-regulation observed in IFNα (500 pg/mL) at the two 
hour time point. The tendency was towards down-regulation of CD36 at the 6 hour time 
point, however, with IFNα seemingly triggering a dose-respondent trend of increasing 
down-regulation. This may indicate that chronic exposure to IFNα can act to reduce CD36 
expression and thereby impair the clearance of apoptotic cells. 
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Figure 3-19 mRNA expression of CD36 in adult control monocytes in response to different environments 
 
Bar charts present relative expression ratios and fold change data for the test conditions. (a) relative expression 
ratios of the gene expression of monocytes at the 2 hour time-point; (b) fold changes of the gene expression of 
monocytes at the 2 hour time-point; (c) relative expression ratios of the gene expression of monocytes at the 6 
hour time-point; (d) fold changes of the gene expression of monocytes at the 6 hour time-point. Apoptotic 
neutrophils (AN) ratios refer to the concentration of AN:monocytes. IFNα, interferon alpha; LPS, 
lipopolysaccharide; TNFα, tumour necrosis factor alpha. 
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3.4.2.3 CR3 Expression 
 
The results following qPCR for CR3 expression are shown in  
Figure 3-20. CR3 expression by monocytes in response to the test conditions was generally 
consistent across the test conditions but varied between the two time points. At the 2 hour 
time-point, monocytes tended to up-regulate CR3 expression. This was particularly 
evidentwith exposure to apoptotic neutrophils (1:1), although at higher concentrations this 
up-regulation decreased. At the 6 hour time-point, expression of CR3 tended to be down-
regulated, and with monocytes exposed to IFNα, fold change decreased, as observed with 
CD36, in a dose-dependent manner. These trends, as with those of CD36, may suggest that 
chronic exposure to IFNα can reduce CR3 expression and may impair phagocytic function as 
a result. 
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Figure 3-20 mRNA expression of CR3 in adult control monocytes in response to different environments 
 
Bar charts present relative expression ratios and fold change data for the test conditions. (a) relative expression 
ratios of the gene expression of monocytes at the 2 hour time-point; (b) fold changes of the gene expression of 
monocytes at the 2 hour time-point; (c) relative expression ratios of the gene expression of monocytes at the 6 
hour time-point; (d) fold changes of the gene expression of monocytes at the 6 hour time-point. Apoptotic 
neutrophils (AN) ratios refer to the concentration of AN:monocytes. IFNα, interferon alpha; LPS, 
lipopolysaccharide; TNFα, tumour necrosis factor alpha. 
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3.5 Summary of Results 
 
 Increased mRNA levels of CD36 were found in JSLE monocytes (p=0.025) but not in 
macrophages. There was no statistical difference between expression levels of MER 
or CR3 in JSLE monocytes or macrophages compared with HC. 
 The measured concentrations of sMER in plasma samples were found to be 
significantly greater in JSLE patients compared with HC (p<0.001) and JIA patients 
(p=0.014). 
 There was a trend towards decreased phagocytosis of E. coli, when adult HC 
monocytes were incubated in JSLE serum and plasma compared with controls, but 
this difference was not statistically significant. 
 No MER cleavage was detected following the exposure of adult HC monocytes to a 
number of test conditions; LPS, IFNα, TNFα and apoptotic neutrophils. The real-
time qPCR results for CD36, MER and CR3 expression in response to these 
conditions were equivocal. 
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4 Discussion 
 
4.1 Interpretation of research findings 
 
4.1.1 Real-time qPCR of monocytes and macrophages 
Overall, data gathered from real-time qPCR shows differential levels of gene expression of 
the phagocytic receptors. In monocytes, CD36 expression was increased in JSLE compared 
with HC (section 3.1.2), and there was no difference with MER and CR3. In macrophages, 
there was no difference found between JSLE and HC according to expression levels of CD36, 
MER or CR3 (section 3.1.3).  
 
The results may indicate that CD36 may be upregulated in JSLE monocytes. These findings 
contrast with that reported for CD36 expression in adult-onset SLE: two previous studies 
(118, 119) found no significant differences between control and adult-onset SLE monocyte 
expression of CD36. The sample sizes across all groups is small, and differences may have 
been detected with greater numbers, though equally, greater numbers would be necessary 
for there to be certainty as to differences in monocyte expression of CD36. 
 
It is unclear what the implications of the differential gene expressions of these receptors 
might be for JSLE pathogenesis and/or its pathology. With the characterised inherent 
phagocyte defects in SLE, one might expect the expression of receptors associated with 
apoptotic cell clearance to be decreased in JSLE than in HC. From analysing the results 
found in this study, one reason for the apparent upregulation of CD36 may be that the 
expressions found are an adaptation to the burden of apoptosis found in JSLE. The 
upregulation may be an unrelated characteristic of the JSLE phagocyte. Alternatively, the 
expression levels of these receptors may be unrelated to the actual function of the 
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phagocyte and the supposed dysfunction is not a result of the gene expression of these 
receptors. The gene expressions may also not be reflective of the actual protein levels 
expressed on the cell surface. The main reasons for such discrepancies as these may 
include the rate of protein turnover, poorly understood post-transcriptional mechanisms of 
protein synthesis, such that protein expression may not relate to mRNA expression, and 
also the potential for error and noise in laboratory experiments. Another disadvantage of 
qPCR data is that it reflects the cumulative total of mRNA from cells but provides no 
information as to the cellular profile of expression, i.e. the number of cells expression 
CD36/MER/CR3. This information could be obtained by flow cytometry analysis of 
monocytes and macrophages to investigate these receptors on a cell-by-cell basis. 
 
4.1.2 sMER ELISA 
The concentrations of sMER were measured in JSLE patients and this was of particular 
interest in light of published data suggesting increased levels in SLE patients compared with 
HC (109). The ELISA kit and methods used were first validated, which was important since a 
number of ELISA assays for cytokines tested within our laboratory were found to have been 
affected by matrix interference (147). The sMER levels were then measured, comparing 
JSLE patients with JIA patients, utilised as an inflammatory control, and HC. The JIA controls 
were particularly important to ensure that any differences found were specific to JSLE and 
not reflective of the inflammation common to both diseases. 
 
The patient samples were age and sex-matched so that the study populations were 
demographically similar. A third of JSLE patients were defined as having active disease at 
the time of sample collection. The “other” category of medications also gives an indication 
of severity, with 20% of patients treated with cyclophosphamide or IVIG, drug treatments 
reserved for refractory forms of disease. 
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sMER concentrations were found to be significantly greater in JSLE patients than in JIA or 
HC (section 3.2.2.2). This echoed results previously described in adult-onset SLE that 
reported greater levels in SLE compared with controls (109). The differences observed 
between the JSLE and JIA concentrations suggest that this amount of sMER may be unique 
to JSLE pathology and not reflected by the general inflammation common to both diseases. 
These greater concentrations of sMER measured are of particular interest because of the 
potential implications they may have for JSLE.  
 
To relate this to the qPCR data reported, presence of sMER may reflect losses incurred by 
phagocytes in JSLE and therefore reduce the amount of MER on the cell surface. More 
interesting still is the notion that sMER actually goes on to act as a competitive antagonist 
for ligands (105) (MER binds to Gas6 or protein S which in turn bridge to the apoptotic cell), 
and so with more sMER found in the plasma, this sMER may reduce the capacity of the 
phagocytes to internalise apoptotic cells using its MER receptors. Thus the impact of MER 
losses may occur in two ways. To confirm the sMER identified by ELISA, immunoblotting 
could be undertaken to determine molecular weight.   
 
Concentrations of sMER were also found to be greater in JIA patients than in HC. Further 
investigation would be required to ascertain the reason for this difference. In the case of 
JIA, the presence of sMER may be the result of the associated inflammatory process. 
Inflammation is a disease feature common to both JSLE and JIA and may, at least in part, 
explain increased sMER concentrations. 
 
Age showed strongly-inverse correlation with sMER concentration in JSLE patients (r=-
0.714, p=0.003) (Figure 3-7). This correlation was not reproducible in either the JIA 
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(r=0.345, p=0.328) or HC (r=0.048, p=0.864) sample populations. In the same respect as 
JSLE often accompanies a more severe disease form of lupus than SLE (79), JSLE is observed 
to affect patients with greater severity in those with the disease from an early age of onset. 
Other factors involved may include different therapeutic regimen, so patients were 
grouped according to concurrent treatment to attempt to discern the potential role of this. 
This suggests that this is a feature unique to JSLE patients, although since JIA and HC sMER 
concentrations were within fairly small ranges (especially compared with those of JSLE), it is 
naturally difficult to use these data to correlate with sMER. Another disadvantage is that 
there were only three JSLE patients included under the age of 10, so it is difficult to predict 
how a greater sample size with more patients in this age range might have altered the 
results. The obvious difficulty however, is that JSLE patients under the age of 10 are a 
subgroup within a juvenile-form of an already rare disease. 
 
A positive correlation of BILAG disease activity score and sMER was observed (r=0.472), 
although the correlation was not statistically significant (p=0.075). The suggestion is that 
sMER concentration could be a useful biomarker, reflective of JSLE disease activity, and 
associated with nephritis and presence of anti-dsDNA (109). A number of haematological 
biomarkers used to monitor JSLE disease were also correlated against sMER concentration; 
ESR, CRP, C3 and C4; but there was no evidence of correlation with these markers (Figure 
3-8). 
 
The potential relationship between sMER concentration and patient gender was also 
investigated. sMER concentration was found to be statistically significantly greater in males 
(Figure 3-9). This appears to add weight to the suggestion of correlation with age, with 
JSLE/SLE usually common in females, however in the young this gender difference is less 
noteworthy. This may be adding to the suggestion that sMER concentration is greater in 
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younger age of JSLE. The males tended to have greater BILAG disease activity scores 
(section 3.2.2.2), linking these discussed factors with disease severity and activity at the 
time of sample collection. The suggestion may be that sMER is increased at times of disease 
flare or increased activity. This would make it a useful biomarker in monitoring JSLE disease 
pathology. 
 
JSLE patients were divided according to drug treatments being utilised at the time of 
sample collection. Potentially, these therapeutics may impact upon the sMER 
concentration found in plasma. The only drug treatment associated with differing levels of 
sMER in patients was hydroxychloroquine, with levels much greater in those not treated 
with the drug (Figure 3-10). Hydroxychloroquine has not been associated with affecting 
apoptotic cell clearance so this may simply represent a chance finding. The statistical power 
is weak, however, with only 3 patients not treated with the drug at the time of sample 
collection. 
 
Observations of corticosteroids in apoptotic cell clearance have presented a number of 
different effects and associations. Recently, they have been shown to augment the 
clearance of apoptotic cells and this was linked to the MER receptor (104). However, there 
is also no indication from the literature that corticosteroids affect the rate of MER cleavage. 
The results from this set of experiments suggest that there is no effect of corticosteroids on 
the level of sMER present in plasma (Figure 3-11) and there is no reason to suspect a role in 
MER loss from the cell surface. 
 
Dividing patients according to medications is difficult, since the effects of certain drugs may 
be long-lasting but in order to group patients, only the drugs they were prescribed at the 
time of sample collection were considered. However, patients could have been receiving 
108 
 
any other drugs in the preceding months. Another difficulty is that the sample size was only 
15 patients and attempting to further characterise these patients reduces the statistical 
power. 
 
4.1.3 Monocyte Phagocytosis of pHrodo E. coli 
With the methods for assessing phagocytosis of pHrodo-stained E. coli first validated and 
optimised, a series of experiments were conducted on homologous adult HC monocytes to 
investigate the role of environment on phagocytosis. Monocytes were tested in JSLE and 
HC serum and plasma samples, with no differences in phagocytic performance in serum or 
plasma. The results indicated that phagocytosis performance is greater in control plasma 
than in JSLE plasma. The difference was, however, not statistically significant, with some 
tests showing greater phagocytosis in JSLE environments. Any differences in phagocytosis 
may be explained by differences found in the serum/plasma of JSLE and HC patients. Two 
of the main ways by which phagocytosis (see 1.3) of E. coli may have occurred are through 
the Fcγ receptors and complement receptors. JSLE patients may, at different times, have 
low levels of complement present and this may explain a defect in phagocytosis occurring 
via this mechanism. 
 
Taken together, phagocytosis was generally greater in JSLE serum and plasma compared 
with control. This negative effect of serum has been reported previously by research into 
adult-onset SLE, in studies testing apoptotic cell clearance. Ren et al (38) and Bijl et al (58) 
both show marked reductions in phagocytosis by monocyte-derived macrophages in SLE 
serum, though one study reported no differences (59) between phagocytosis in HC or SLE 
serum. The implication is that a contribution is made to the impairment of phagocytes by 
the environment, seeming to suggest the involvement of extracellular factors in the 
hypothesised failing of apoptotic cell clearance. 
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In this study, only (adult) HC monocytes were tested, but reports are conflicting as to the 
potential of intrinsic cellular defects affecting phagocytosis. Herrmann et al (55) and Ren et 
al (38) reported decreased phagocytosis by SLE monocyte-derived macrophages, and Tas et 
al (57) found no differences in binding capability but identified defective internalisation. 
However, Bijl etl al (58) found no differences in phagocytic performance when comparing 
HC and SLE monocyte-derived macrophages in HC serum.  
 
4.1.4 Monocyte Stimulation 
Having exposed adult HC monocytes to a number of settings associated with lupus, an 
sMER ELISA was conducted to assess for evidence of MER cleavage. There was no sMER 
recovered from any of the test conditions. This was unexpected of the LPS-exposed 
monocytes, which was used at a concentration (50 ng/mL) that had been reported as 
sufficient to cause the cleavage of MER by Sather and colleagues (105). LPS was included as 
a positive control and the failure to detect sMER through ELISA reflects that this assay did 
not work to this end. It was difficult to apply similar conditions, however, as the authors 
used a murine macrophage cell line (J774), the cell count was reported as confluency, and 
MER cleavage was measured by immunoblotting. Exposure of cells to IFNα, TNFα and 
apoptotic neutrophils did not result in MER cleavage from the surface of the monocytes. 
This suggests that it is one or more other factors that are responsible for triggering MER 
cleavage. It is not necessarily the case that there was no MER present in supernatant, but it 
may have been at a concentration lower than was detectable by spectrophotometry. The 
number of monocytes may have been too small, or the incubation times may have been 
too short to allow for cleavage. JSLE is a chronic disease and the monocytes and 
macrophages of JSLE are therefore exposed to cytokines such as those tested for a longer 
period than 6 hours. Repeating the experiment with a greater number of cells, for a 
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number of time-points, may result in measurable levels. Flow cytometry could be used to 
assess the MER expression profiles of cells before and after stimulation with test 
conditions. 
 
The mRNA from these monocytes was also tested through real-time qPCR to investigate for 
any effects that these conditions had caused in the genetic expression of the three 
receptors of interest in this project; CD36, MER and CR3. The changes in gene expression 
were fairly small, with all recorded fold changes between -3 and +3. In monocytes exposed 
for 2 hours, MER expression was generally downregulated, but at the 6 hour time-point the 
majority of expression was upregulated. This was in contrast to the general trends of CD36 
and CR3, where at 2 hours gene expression was upregulated, but after 6 hours of exposure 
these markers were downregulated. CD36 and CR3 also shared a common reaction to 
increasing concentrations of IFNα, with decreasing levels of gene expression in response. At 
the 6 hour time-point, IFNα-exposed monocytes appeared to upregulate MER expression 
but this was not observed at the 2000 pg/mL concentration making this association 
unclear. This was, however, only observed at the 6 hour time point and not with monocytes 
exposed for 2 hours. These two time points were tested in turn and with different blood 
donors so may reflect an element of individuality in the response to different conditions.  
 
How the JSLE/SLE environment may affect phagocyte gene expression or MER cleavage has 
not been investigated to date and this represents the first attempt to characterise any 
potential relationship between them. 
 
4.2 Study limitations 
All elements of the research conducted were approached rigorously to ensure the 
underlying methodology was sound. There are, however, a number of limitations of the 
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research which should be considered alongside the results found and conclusions reached. 
Time represented a major constraint, with needing to first develop and learn laboratory 
skills from scratch, and then the process of validating and optimising experiments; only 
after all these steps were completed could experiments be undertaken with results that 
would contribute to this thesis. 
 
The real-time qPCR data for gene expressions of receptors in monocytes and macrophages 
are based on fairly small sample sizes. This is especially the case with JSLE macrophages 
(n=3). This lessens the extent to which the data can be interpreted, as a greater sample size 
may serve to alter the findings. However, the use of both macrophages and their 
precursors monocytes increases the power as, in general, trends were consistent in both 
cell types. 
 
The cell culture technique for the differentiation of monocytes into macrophages in vitro 
also presented difficulties. Frequently this process was affected by contamination in spite 
of aseptic procedures with all work conducted within the sterile field of a ventilated hood. 
This continued to cause problems throughout the year and made progression difficult. 
 
The RNA extraction process yields a greater amount of RNA with better quality, often 
relative to greater numbers of cells. After cell separation there may be relatively low 
numbers of CD14+ cells, dependent in the main on the amount of whole blood available at 
the start. Whilst this could be accounted for when procuring adult HC blood, JSLE and 
control plasma samples may only be 5 mLs of blood. Further to this, JSLE patients are often 
found to have low levels of white cells, and in particular their monocytes have been 
observed to have a reduced capacity to adhere plastic (57). The result of these factors may 
be RNA that falls outside of the desired range of quantity and quality; these were 
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sometimes tested and then used providing the reference gene appeared to be stably 
expressed and there were no obvious abnormalities in subsequent PCR experiments. 
 
The phagocytosis assay proved to be quite a difficult experiment to validate and optimise. 
In the end, adult HC monocytes were tested in JSLE and control serum and plasma. Ideally, 
macrophages would also have been tested under these conditions, then phagocytes from 
JSLE and paediatric controls also. The ultimate endpoint would have been the development 
of a phagocytosis assay in which apoptotic cell clearance was investigated as opposed to 
bacterial uptake.  
 
The monocyte stimulation experiments used relatively small cell numbers (around 4 x 105 
cells per test condition) so the RNA extracted was of poor quality and quantity. These were 
used and tested, however, and the reference gene expression was stable and expressions 
of receptors appeared unaffected, and the use of two separate cell sets with two different 
time points adds weight to the results. With different donors and performed separately, 
the nature of the neutrophils in which apoptosis was induced differed between the two 
experiments, but there could never be exactly the same response to apoptotic induction by 
cells. This may, in part, explain the discrepancies in the receptor expression levels observed 
between monocytes exposed for 2 hours and those exposed for 6 hours. 
 
JSLE is a uniquely variable disease, with severity different from one patient to the next, and 
diagnosis is made upon satisfaction of 4 or more of 11 criteria. The result is a group with 
common pathological processes but with widely varying afflictions and manifestations. 
There is also a large range of therapeutic options available to clinicians, much of which is 
aimed at immunosuppression. These factors can present challenges to research in that 
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results can be affected in a number of different ways. JSLE is also a rare disease and 
therefore hospital attendances and blood samples are relatively infrequent.  
 
4.3 Study strengths 
Much of the pathogenesis of JSLE, and indeed adult-onset SLE, is not yet understood. As 
such, it is imperative that research is undertaken to attempt to characterise the associated 
disease processes. This is especially important in JSLE, which is often more severe than 
adult and may actually differ from SLE in currently unknown ways. This research project has 
involved rigorous scientific methodology to attempt to add to the knowledgebase of JSLE 
pathophysiology, at one of the considered earliest steps in the process. The functional 
phagocytosis assay showed results which appear consistent with similar reported studies in 
adult-onset SLE, therefore strengthening the hypothesis of the dysfunction of phagocyte 
function in lupus as a whole. sMER concentrations were also found to be greater in JSLE, as 
had been reported in adult-onset SLE, and the results found in relation to those of JIA 
suggest that this presence of sMER at these concentrations appears unique to the JSLE 
autoimmune process. Attempts to ascertain the effect of lupus-associated cytokines/other 
environmental factors gave rise to inconclusive results but this is a novel, previously untried 
set of experiments. All of the reported results are unique to JSLE and some are unique to 
both JSLE and adult-onset SLE, and can be precursors for additional research. 
 
4.4 Potential research directions 
There are many avenues available for future research projects to take with much yet to 
investigate. Results described in this study could also be enhanced by greater sample sizes, 
giving results greater statistical power. At the gene level, expression of other phagocytic 
receptors could be measured to look to capture differences between JSLE and control 
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monocytes, for example TIM4 and MARCO, two receptors associated with apoptotic cell 
clearance.  
 
A natural progression from gene expression measurement would be to investigate protein 
levels through Western Blots. Assessment of the same receptors would indicate if the levels 
found at gene level were reflective of cell receptor expression, any discrepancies between 
these would be of interest and would naturally lead to investigation as to why these 
differed. 
 
The results of the measurement of sMER levels in JSLE could be built upon by the 
continuation of investigation as to the potential triggers of MER cleavage, through further 
phagocyte stimulation assays. Experiments could be repeated in monocytes over a longer 
time-course, and macrophages could be exposed to the same environments. Cells could 
also be exposed to other cytokines associated with SLE, such as IL-6 (72, 148), IL-17 (149) 
and IL-21 (150). Cleavage has been observed to occur in response to LPS and PMA exposure 
in the literature (105). The identity of the molecule containing antigens found through the 
sMER ELISA experiments could be confirmed by immunoblotting to confirm molecular 
weight. The profile of monocytes and macrophages, with respect to MER expression, could 
be investigated through measurement by flow cytometry. Another potential direction of 
research is to investigate the effect of greater concentrations of sMER. 
 
One method by which this could be investigated would be by further extension of the 
phagocytosis assay. The key would be successful validation and optimisation of a method of 
measuring phagocytosis of apoptotic cells by monocytes and macrophages. To these, 
plasma samples of known sMER concentration (confirmed by ELISA) could be added to 
assess the potential effect that the presence of sMER may exert on phagocytic function. 
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This could be done further to adding known quantities of exogenous MER and/or MER 
antibodies. The former would act as a control for the presumed action of sMER, and the 
latter would act as a blocking control. 
 
There are also a number of interesting directions the phagocytosis assay could take, not in 
only relation to MER. Continuation of the phagocytosis assay described here could be used 
to investigate the ability of JSLE and control monocytes and macrophages to phagocytose 
either in JSLE or control serum or plasma. This would give indication as to whether any 
phagocytic impairment was reflective of inherent cellular defect or the proinflammatory, 
autoimmune environment. These could be conducted testing bacterial uptake and 
apoptotic cell uptake, comparing phagocytic function in both cases. Of particular relevance 
and interest to the research group would be the uptake of dying neutrophils which have 
been suggested as presenting a great apoptotic burden to the body (39). 
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5 Conclusion 
 
Phagocytosis is an essential functional process designed to clear foreign bodies, debris, and 
cells undergoing apoptosis. Its underlying mechanisms are complicated and vary depending 
on circumstance. In the autoimmune disease JSLE, phagocytosis is believed to be impaired. 
This impairment, in relation to the clearance of dying cells, is thought to be a key factor 
involved with the pathogenesis of the disease.  
 
In this study, JSLE monocytes were found to up-regulate gene expression of the phagocytic 
markers CD36 compared with HC, though no differences in MER or CR3 expression; there 
were no differences between JSLE and HC in macrophage expression of CD36, MER or CR3. 
Increased CD36 expression may suggest that JSLE monocytes may be adapted in light of a 
greater apoptotic cell burden comprised of cells such as neutrophils which have been 
shown undergo an accelerated cell death process in JSLE.  
 
Control monocytes and macrophages were negatively affected in their capacity to 
phagocytose bacteria when exposed to JSLE plasma, suggesting that any phagocytic defect 
could be the result of extracellular factors. A cleaved form of the receptor MER, sMER, was 
found at greater concentrations in JSLE patients than in either inflammatory controls (JIA) 
or HC, as has been observed in adult-onset SLE. The increased quantities of sMER are 
probably causing a number of effects, such as reducing the cell’s MER expression, but also 
antagonising the process of apoptotic cell clearance by competing for ligands.  
 
Factors including IFNα, TNFα and apoptotic neutrophils failed to provide unequivocal 
evidence as to any potential role they may have in altered monocyte and macrophage 
phenotype, with no clear resulting changes in CD36, MER and CR3 gene expression levels. 
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Research is ongoing with the aim to discover more about the role the phagocytes may be 
playing in JSLE pathogenesis, with the ambition that through better understanding of 
disease processes may better therapeutics be tailored.   
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Appendix 2: Information sheets for the UK Juvenile Lupus Cohort 
Study and Repository 
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Age-appropriate information sheets are given to patients: the above reproduced 
information sheets are aimed at patients of 16 years or older. 
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Appendix 3: Patient’s consent form for the UK Juvenile Lupus Cohort 
Study and Repository 
 
 
 
Example consent form (used if patient is able to consent for him/herself) 
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Appendix 4: mRNA expression of JSLE and HC Monocytes and 
Macrophages 
 
 CR3 CD36 MER 
C136a 0.7206 0.3573 0.1718 
C137a 0.6945 0.4048 0.4197 
C138a 0.7251 0.7781 0.2040 
C140a 1.1407 0.4795 0.4889 
C142a 0.8059 0.5756 0.3052 
C143a 1.8595 0.6693 0.2754 
        
L17p 0.3163 0.5336 0.3751 
L21g 0.8847 1.5133 0.7596 
L30i 0.6765 1.2755 0.5482 
L42l 0.5550 0.9611 0.1021 
L52b 1.2077 0.7350 0.7343 
L55c 0.6176 0.9650 0.3609 
Monocytes mRNA expression 
 
 CR3 CD36 MER 
C135a 0.3122 0.4280 0.5857 
C136a 0.3900 0.5294 0.3999 
C137a 0.8340 0.5848 0.9561 
C138a 0.1540 0.4122 1.4129 
C142a 1.4024 1.1415 1.1330 
C143a 2.2203 1.5129 2.0548 
C152a 3.7391 0.5672 2.1093 
C154a 2.2350 0.6542 1.2650 
C155a 1.9328 0.8280 1.1397 
    
L17p 0.2629 0.6355 0.7368 
L40h 0.6225 1.0196 0.8474 
L41k 0.4857 2.1756 0.8629 
Macrophages mRNA expression 
 
Relative expression ratios of monocytes and macrophages 
C, Control; L, Lupus (JSLE) 
Numbers indicate anonymised unique patient/control code 
Lower case letter codes for the case attendance number 
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Appendix 5: sMER ELISA 
 
 Blank ng/ml x 5 
L2e 0.689 2.224 11.120 
L3f 1.070 4.068 20.338 
L4j 1.208 4.889 24.445 
L17h 1.014 3.760 18.800 
L21d 0.872 3.031 15.155 
L30e 1.460 6.599 32.995 
L33d 0.692 2.236 11.180 
L35h 0.677 2.174 10.869 
L40e 0.775 2.587 12.933 
L43f 1.101 4.245 21.225 
L45k 0.613 1.930 9.649 
L46c 1.574 7.462 37.309 
L49d 0.979 3.570 17.852 
L50f 0.453 1.391 6.957 
L51d 0.739 2.431 12.155 
J3c 0.683 2.200 10.999 
J15b 0.635 2.012 10.062 
J24b 0.988 3.621 18.103 
J25b 0.710 2.310 11.548 
J26c 0.667 2.134 10.672 
J27b 0.644 2.045 10.225 
J40b 0.475 1.459 7.295 
J41a 0.731 2.397 11.985 
J43a 0.550 1.703 8.515 
J44a 0.458 1.407 7.033 
C54a 0.369 1.152 5.762 
C59a 0.674 2.164 10.820 
C60a 0.393 1.216 6.081 
C61a 0.465 1.428 7.140 
C66a 0.433 1.330 6.651 
C67a 0.567 1.764 8.819 
C71a 0.558 1.732 8.662 
C73a 0.542 1.677 8.387 
C74a 0.396 1.225 6.123 
C76a 0.556 1.724 8.619 
C85a 0.324 1.037 5.184 
C87a 0.391 1.212 6.061 
C90a 0.336 1.067 5.334 
C91a 0.311 1.005 5.025 
C100a 0.398 1.230 6.151 
 
Absorbances measured by spectrophotometer from ELISA assay; concentrations calculated 
using the standard curve generated; corrected sMER concentrations, multiplied by 5x to 
correct for 1 in 5 dilution. 
C, Control; J, JIA; L, Lupus (JSLE) 
Numbers indicate anonymised unique patient/control code 
Lower case letter codes for the case attendance number  
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Appendix 6: Monocyte Phagocytosis of pHrodo E. coli 
 
  % Phagocytosis 
C154a 34.4 
C169a 48.2 
C159a 46.6 
C132a 43.3 
C171a 50.9 
C174a 27.7 
    
L42h 16.6 
L52i 37.2 
L59a 39.1 
L43k 29.1 
L50k 32.6 
 
Measured phagocytosis of pHrodo E. coli by adult HC monocytes in plasma samples 
(expressed as a percentage of all monocytes) 
C, Control; L, Lupus (JSLE) 
Numbers indicate anonymised unique patient/control code 
Lower case letter codes for the case attendance number 
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Appendix 7: Monocyte Stimulation 
 
  MER CD36 CR3 
Exp 1 Mo alone 0.9353 0.2104 0.3752 
Exp 1 LPS 0.4552 0.2289 0.4372 
Exp 1 IFNα 100 0.9436 0.2153 0.6584 
Exp 1 IFNα 500 0.4695 0.3973 0.7562 
Exp 1 IFNα 1000 1.1780 0.2400 0.4773 
Exp 1 apoptotic neutrophils 1:1 0.6314 0.2584 0.8886 
Exp 1 apoptotic neutrophils 2:1 0.7795 0.2404 0.5657 
Exp 1 apoptotic neutrophils 4:1 0.3627 0.1816 0.4799 
Exp 2 Mo alone 0.8955 2.4304 1.8493 
Exp 2 LPS 0.6469 4.8915 1.5194 
Exp 2 TNFα 100 1.3589 1.8905 1.2050 
Exp 2 TNFα 500 1.0073 1.6736 1.2376 
Exp 2 TNFα 1000 1.6153 1.2224 1.0158 
Exp 2 IFNα 100 1.4106 0.9043 0.8640 
Exp 2 IFNα 500 1.8420 1.8434 1.8392 
Exp 2 IFNα 1000 1.0579 2.2089 1.3020 
Exp 2 IFNα 2000 0.6698 2.3082 1.6703 
Exp 2 apoptotic neutrophils 1:1 1.0307 3.4161 2.1381 
Exp 2 apoptotic neutrophils 2:1 0.9306 0.5424 2.5552 
Exp 2 apoptotic neutrophils 4:1 0.7351 2.2392 1.6565 
Relative expression ratios of mRNA from monocytes exposed to different conditions 
 
  MER CD36 CR3 
Exp 1 LPS -2.3457 1.0281 1.1567 
Exp 1 IFNα 100 -1.0497 1.0943 1.7291 
Exp 1 IFNα 500 -2.2974 1.5157 1.9588 
Exp 1 IFNα 1000 1.2746 1.1567 1.2658 
Exp 1 apoptotic neutrophils 1:1 -1.5263 1.0570 2.2974 
Exp 1 apoptotic neutrophils 2:1 -1.1975 1.0281 1.4845 
Exp 1 apoptotic neutrophils 4:1 -2.7702 -1.3472 1.2483 
Exp 2 LPS -1.2834 1.3013 -1.2311 
Exp 2 TNFα 100 1.9053 -1.4439 -1.5369 
Exp 2 TNFα 500 1.3379 -1.6021 -1.5052 
Exp 2 TNFα 1000 2.4623 -2.0994 -1.8404 
Exp 2 IFNα 100 2.0000 -2.4116 -2.1287 
Exp 2 IFNα 500 2.7321 -1.4641 -1.0281 
Exp 2 IFNα 1000 1.5157 -1.4439 -1.4439 
Exp 2 IFNα 2000 -1.2658 -1.2397 -1.1251 
Exp 2 apoptotic neutrophils 1:1 1.2226 1.2142 1.1487 
Exp 2 apoptotic neutrophils 2:1 1.09 -2.9485 1.3660 
Exp 2 apoptotic neutrophils 4:1 -1.02 -1.4439 -1.1408 
Fold changes of mRNA from monocytes exposed to different conditions 
 
Exp (experiment) 1: 2 hour exposure; Exp 2: 6 hour exposure 
Mo, monocytes; LPS, lipopolysaccharide; IFN, interferon alpha; AN, apoptotic neutrophils; 
TNF, tumour necrosis factor alpha 
